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ABSTRACT

Author: Lin, Jenny, B. PhD
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Title: Development of Targeted Pro-angiogenic Therapies for Ischemic Diabetic Foot Ulcer
Repair.
Major Professor: Alyssa Panitch
Between 15-25% of diabetic patients develop chronic foot ulcers within their lifetime. These
ulcers are characterized by delayed wound healing, are highly susceptible to infection, and can
lead to lower-limb/foot amputation. Impaired ulcer healing is most often due to ischemia and
insufficient formation of new vessels in the wound bed, as well as rapid turnover of healing tissue
by excessive matrix metalloproteinase (MMP) activity. To improve healing of chronic ischemic
wounds, researchers have sought to increase angiogenesis at the wound site using growth factors
such as vascular endothelial growth factor (VEGF). VEGF is a key angiogenic mediator and
uniquely participates in multiple aspects of wound healing including revascularization, reepithelialization, and collagen deposition. However, the clinical success of growth factor therapies
such as VEGF has been limited largely due to the overexpression MMPs in the wound environment
that degrade or inactivate the growth factors. Furthermore, non-targeted angiogenic growth factor
therapies raise significant concerns because they are not restricted to the wound site, but potentially
diffuse into systemic circulation and cause malignancies.

This thesis reviews current advances in understanding the pathogenesis and pathophysiology of
the compromised wound healing environment leading to DFUs with particular emphasis on the
roles of neovascularization and matrix remodeling. It also addresses recent progress in VEGF
therapy for DFUs and the current limitations in clinical translation imposed by co-existing
pathophysiological defects of diabetic wound healing. Given the current understanding of the
impaired healing components suggesting a need to correct multiple derangements while
maintaining efficacy in the complex and highly proteolytic environment, we propose multiple
collagen-targeted, degradation resistant, proangiogenic therapies to activate and potentiate VEGF
pathways and simultaneously protect existing collagen matrices. Specifically, we discuss the
development of VEGF-loaded collagen-binding nanoparticles and two variants of engineered

xx
decorin mimetics functionalized with pro-angiogenic VEGF-mimicking or αvβ3 integrin-binding
peptides to increase vascularization of the wound bed. Both the nanoparticles and the angiogenic
proteoglycan mimics can be targeted to endogenous collagen or exogenous collagen dressings by
a collagen-binding peptide and could be used in combination to exploit VEGF activation and
potentiation. This project (i) develops a thermosensitive nanoparticle VEGF-delivery system, (ii)
develops and characterizes pro-angiogenic peptide-functionalized decorin mimics, and (iii)
assesses the in vitro and in vivo angiogenic potential of these pro-angiogenic decorin mimics as
proof-of-concept supporting their potential to accelerate ischemic dermal wound healing in animal
models.

1

1. INTRODUCTION: COMPLEX PATHOPHYSIOLOGY OF IMPAIRED
CUTANEOUS WOUND HEALING IN DIABETES POSES BARRIERS
TO TRANSLATION OF ANGIOGENIC GROWTH FACTORS

1.1

Significance and Epidemiology: Diabetic Foot Ulcers
In 2015, the Center for Disease Control and Prevention estimated a population of 30.3

million diabetic Americans (1), up to 25% of whom will develop diabetic foot ulcers (DFUs) in
their lifetime (2, 3). The majority of DFUs, which affect both type I and type II diabetics, develop
from a combination of peripheral neuropathy and vascular insufficiency (ischemia) and are thus
categorized to have mixed neuropathic and ischemic pathologies (4, 5). Deficits in the macro- and
microcirculation are a major factor leading to delayed wound healing (6), and DFUs with an
ischemic component caused by concurrent peripheral vascular disease (PVD) and/or
microangiopathy are more severe with higher mortality rates (4, 5). Non-healing foot ulcers are
prone to serious infections requiring limb amputation; in fact, diabetic complications account for
the majority of non-traumatic lower-limb amputations (1, 7) with 5-24% of DFUs leading to lowerlimb amputation 6-18 months after the initial evaluation (4). Moreover, ulcers and other foot
complications comprise 20% of diabetes-related hospitalizations and thus represent a significant
health burden in the United States (8). Accelerating DFU healing would reduce the need for lowerlimb amputation, improve survival of patients suffering from DFUs, and decrease diabetes-related
hospitalizations.

1.2

Current Treatments for Non-Healing Chronic Diabetic Foot Ulcers
The current gold standard for DFU treatment includes wound debridement, antibiotic

management of infection, off-loading of the ulcer, and revascularization surgeries if indicated (4,
9). Although many wound dressings are available to protect the DFU and promote a moist
environment (10), the efficacy of such wound dressings in DFU healing remains unclear (11); a
meta-analysis of recent randomized control trials using advanced wound dressings alone (ie.
without growth factors or living cellular components) showed no significant advantages for
advanced dressings, such as alginate, over basic wound care (11). If 1 month of traditional
management provides insufficient healing, additional advanced DFU therapies including cell-
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based skin replacements, such as Dermagraft (12) and Apligraf (13), or growth factor therapies,
such as Regranex (14) may be indicated. However, only Apligraf is FDA approved for ischemic
DFU. Currently, clinically effective DFU treatments, specifically those applicable to ischemic
DFUs, remain a significant concern, but developing these treatments has been complicated by
the multiple concurrent defects in the DFU environment. These pathophysiological barriers are
exemplified by the limited successes in clinical translation of angiogenic growth factor therapies.
Future therapies may be more successful if they are combination treatments that take into
account the interrelationships between inflammation, angiogenesis, and ECM remodeling.

1.3

Impaired Neovascularization in Diabetic Wound Healing
Diabetes is known to impair post-ischemic neovascularization in multiple parts of the body,

including the lower-limbs (24, 25). This decreased ability to create new blood vessels severely
affects the proliferation/granulation phase of wound healing, which requires angiogenesis to
sustain actively proliferating fibroblasts and keratinocytes. Specifically, vascular endothelial
growth factor (VEGF) appears to be crucial to granulation since its neutralization causes a severe
healing defect (26). Reduced neovascularization in diabetics has been attributed to dysregulation
and insufficient levels of angiogenic growth factors (27) (VEGF (28-30), EGF (31), aFGF and
bFGF (31, 32), KGF (32), or PDGF (30, 33-35)), endothelial dysfunction with reduced angiogenic
response (36), and reduced endothelial progenitor cell recruitment (37-39).
1.3.1

Cell Dysfunction Leads to Insufficient and Uncoordinated Angiogenic Signals
The regulation of both growth factor levels and timing of induction are important in

orchestrating wound repair and are abnormal in diabetic wounds. Many cells, including
macrophages, keratinocytes, fibroblasts, and endothelial cells, normally secrete angiogenic growth
factors, such as PDGF, VEGF, EGF, aFGF, bFGF, and KGF, to mediate the wound healing process
(15-17). However, cellular dysfunction within the diabetic wound bed causes both uncoordinated
and decreased levels of these growth factors. For example, endogenous PDGF and PDGFR are
both decreased in diabetic wounds compared to acute wounds (18, 19). VEGF production in the
diabetic wound bed is also reduced due to multiple factors, including reduced expression in
diabetic keratinocytes (20), reduced production by diabetic fibroblasts (21, 22), reduced
production by diabetic macrophages (23, 24). Diabetes was shown to decrease HIF-1α
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transactivation, leading to blunted VEGF-induction after hypoxia (21, 22). In diabetic mouse
models, wound keratinocytes exhibit reduced induction of FGFs (25, 26). DFU skin biopsies also
show that both keratinocytes and endothelial cells at the DFU margin also fail to upregulate VEGF
and VEGFR2, PDGF and PDGFR, EGFR, IGF-1, and NOS2 (27).
Given these derangements in growth factor release profiles, many researchers have
investigated angiogenic factor supplementation to alleviate impaired healing. Numerous studies
show the benefits of angiogenic growth factor supplementation in wound healing in diabetic
rodent models, but only PDGF has proven sufficient clinical efficacy in diabetic patients (28,
29).
1.3.2

Endothelial Dysfunction Decreases Angiogenic Responsiveness
Diabetes is a well-known cause of endothelial dysfunction, which encompasses a broad

variety of dysregulated endothelial functions, including diminished ability to mediate vasodilation,
disrupted intimal layer barrier function, abnormal leukocyte recruitment and diapedesis, decreased
proliferation and migration, and abnormal angiogenic responses (30).
In addition to insufficient growth factor levels, impaired neovascularization in diabetics is
compounded by endothelial dysfunction, reflected by decreased responsiveness to local growth
factors and exemplified by decreased proliferation and migration (30-33) and increased apoptosis
(34, 35) in endothelial cells cultured in hyperglycemic media. Decreased endothelial proliferation
in diabetics can, at least in part, be attributed to accelerated accumulation of advanced glycation
end-products (AGEs) and oxidative stress signaling through receptor for AGEs (RAGE) to
decrease endothelial responsiveness to angiogenic factors (36-38). For example, RAGE-mediated
VEGFR2 degradation subsequently attenuates signaling transduction of VEGF (38). It is apparent
then that introducing greater levels of growth factors might not adequately compensate for
decreased angiogenic responses if the number of receptors is reduced and all receptors are saturated.
It follows that therapeutic modulation of increasing overall receptor levels and/or decrease
degradation of receptors may be necessary in conjunction to administering increased growth
factors to achieve appropriate angiogenic responses.
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1.3.3

Reduced Endothelial Progenitor Cell Recruitment and Pro-Angiogenic Paracrine
Signaling Capacity
During tissue granulation, both local endothelial cells and bone marrow-derived endothelial

progenitor cells (EPCs) participate in neovascularization. Exogenously administered EPCs have
been shown to accelerate wound closure in diabetic mice by incorporating into the vasculature and
increasing angiogenesis and granulation (39). Endogenous EPCs mobilize into systemic
circulation through VEGF-induced endothelial nitric oxide synthase (eNOS) activation (39, 40)
and are recruited to the wound by SDF-1α, where they promote angiogenesis by expressing high
levels of VEGF and bFGF (39, 40). In diabetes, EPCs have both impaired mobilization (due to
reduced eNOS activity) and homing (due to reduced SDF-1α at the wound), resulting in fewer
EPCs present in circulation (41-43) and at the wound site (43), respectively. Furthermore, EPCs
successfully homing to the wound site may fail in paracrine signaling, as HUVECs exposed to
diabetic-EPC-conditioned media display reduced tube formation in comparison to their nondiabetic media equivalents (42). Clinical studies of EPCs harvested from diabetic patients support
this notion of EPC dysfunction in the diabetic environment (44), which is mediated by oxidative
stress resulting from inappropriately reduced eNOS activity (45).

1.4

Dysregulated ECM Remodeling in Diabetic Wound Healing
The ECM serves multiple essential purposes within a healing wound, as it both regulates

growth factor levels through binding and provides a support for cell attachment and proliferation
(46). A balance in ECM synthesis by parenchymal cells and ECM degradation by MMPs is integral
to successful wound closure, and this balance is disturbed in diabetes.
1.4.1

Abnormal ECM Synthesis
Several growth factors including TGF-β, IGF, PDGF, EGF, and FGF are involved in

promoting ECM synthesis (47, 48). Many studies have shown that collagen, a predominant skin
ECM component, is reduced and abnormally organized in the diabetic wound (47, 49-52), leading
to decreased tensile strength in both uninjured (53) and injured (47, 54) diabetic skin. Bitar et al.
showed that the reduction in tensile strength of wounded skin directly correlated with the induction
of diabetes by STZ in a diabetic rat model and is partially restored by a single application of TGFβ (47), indicating the importance of growth factors such as TGF-β and IGF in maintaining
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appropriate ECM levels in wounded tissue (47). Interestingly, while TGF-β and IGF levels were
decreased in diabetic wounds, transcription of TGF-β was actually increased, suggesting posttranscriptional inhibition of TGF-β expression (49). Since TGF-β also inhibits collagenase
induction by other growth factors (EGF and bFGF) and synergistically increases TIMP
expression(55), decreased TGF-β may also reduce TGF-β-mediated collagenase suppression,
contributing to increased collagenase activity.
Since fibroblasts are the main cells involved in collagen synthesis, another possible source
of dysregulated collagen synthesis is diabetic fibroblast dysfunction. For example, fibroblasts
isolated from DFU have exhibited decreased response to growth factors (56) and hypoxia (21) and
have impaired proliferation, indicating a change to a senescent phenotype (57-60). Work by
Hehenberger et al. suggests that factors specific to the diabetic wound are responsible for this
dysfunction, since fibroblasts from uninjured skin (both diabetic and non-diabetic) have the same
proliferation rates (58). Fibroblasts from uninjured skin of diabetic mice also did not have impaired
proliferation, but did show reduced migration (21), indicating that even though fibroblast
proliferation is not affected by diabetes, other baseline diabetic fibroblast defects may be present.
Research also suggests there is a pre-existing abnormality in ECM maintenance that
predisposes diabetic skin to injury and may propagate through to impair the wound healing process
(49, 53). Bermudez et al. has shown that the total collagen content of dermal ECM is reduced in
uninjured diabetic skin (53), which Caskey et al. suggests is due to posttranscriptional repression
by miRNA-25 and miRNA-29a (49). Collagen glycation may also account for unstable collagen,
since glycated collagen correlates strongly with collagenase activity leading to accelerated
collagen breakdown (52) and has been shown to delay wound healing, decrease biomechanical
properties, and decrease deposition of other ECM proteins, like fibronectin and elastin (61).
The ECM serves multiple essential purposes within a healing wound, as it both regulates
growth factor levels through binding and provides a support for cell attachment and proliferation
(46). A balance in ECM synthesis by parenchymal cells and ECM degradation by MMPs is integral
to successful wound closure, and this balance is disturbed in diabetes. This suggests that an
exogenous ECM tissue replacement such as a supplemental collagen matrix that integrates into the
healing wound may be beneficial in improving ECM organization and integrity.
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1.4.2

Excessive Metalloproteinase Activity
Although normal acute wound healing involves MMP induction in the wound environment

(62, 63), many studies have implicated excessive and prolonged (64) MMP activity (specifically
MMP-2, MMP-8, and MMP-9) in non-healing DFUs (65-72); elevated MMP-9 (66, 67, 70, 73, 74)
in DFU has been shown to predict poor healing. Other groups have additionally identified an
elevated ratio of MMP-9 to TIMP-1 as a predictor of the non-healing state (65) and an elevated
ratio of MMP-1 to TIMP-1 as a predictor of successful healing (66). Similar MMP imbalances
have been identified in diabetic wounds (47, 64) and uninjured skin fibroblasts (21) from diabetic
rodent models. Furthermore, expression of TIMP-2 is reduced in DFU (68), and TIMP-3 reduction
was found to be specific for ischemic but not neuropathic DFUs (75). These altered protease and
protease inhibitor levels result in accelerated degradation and excessive turnover of healing tissue
and essential growth factors responsible for coordinating wound resolution (47). Modulation of
these MMPs has been shown to increase collagen synthesis and improve healing in diabetic rodent
models (76-78).
Elevated MMP levels may arise from diabetes-induced abnormalities of parenchymal cells.
Recently, keratinocytes were found to upregulate MMP-9 transcription through loss of focal
adhesion kinase (FAK) signaling within epithelium and also cause fibroblast downregulation of
TIMP1 in a paracrine manner (79). This mechanism may be relevant to diabetic wound healing
since hyperglycemia (80) and glycoaldehyde-modified AGE-BSA (81) have been found to impair
FAK activation and results in a corresponding increase in MMP-9 after exposure to AGE-BSA
(81). In another example, uninjured diabetic fibroblasts are found to secrete twice the normal
amount of latent pro-MMP-9, although active MMP-9 is not significantly elevated from nondiabetic controls (21). However, within the first 4 days of injury in diabetic mouse wounds,
significantly higher levels of activated MMP-9 are observed (64). The increased basal levels of
pro-MMP-9 in diabetics likely serve as an abundant depot that converts to the activated form upon
injury. Together decreased synthesis of ECM and accelerated degradation in the diabetic
environment leads to excessive turnover of healing tissue and MMP-susceptible growth factors.
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1.5

1.5.1

VEGF for Therapeutic Angiogenesis and Barriers to Clinical Translation
The Promise of VEGF Therapy for Ischemic DFU
To improve ischemic DFU healing, researchers have sought to stimulate angiogenesis by

increasing growth factors at the wound site, in hope of restoring blood flow and improving the
formation of granulation tissue (a loose fibrovascular tissue characterized by blood vessels,
collagen, and fibroblasts) in the healing process. VEGF has been identified as one of the most
potent and rate-limiting angiogenic factors (82) especially integral to the response to ischemia (83),
while simultaneously acting on keratinocytes and fibroblasts to stimulate re-epithelialization and
collagen deposition within the treated area (84-86). VEGF therefore uniquely participates in
multiple aspects of wound healing, including angiogenesis, epithelialization, and collagen
deposition during tissue granulation (85). Furthermore, defective angiogenesis may result, at least
in part, from a combination of reduced VEGF levels and/or decreased VEGF receptor expression.
Currently, VEGF supplementation has shown promise in diabetic rodent models through both
exogenous application (87-89) or gene therapy (84, 90, 91). VEGF supplementation has also
demonstrated effectiveness in ischemic injuries, where it has increased granulation tissue
formation up to 150% in ischemic wounds in non-diabetic rabbits (83), alleviated non-diabetic
PVD ischemia in clinical trials (92) and non-diabetic rodent models of hind-limb ischemia (93),
and improved neovascularization and tissue survival in ischemic skin flaps in rats (94).
1.5.2

Clinical Limitations of VEGF Therapy for Ischemic Diabetic Foot Ulcers
A significant barrier to effective VEGF therapy is the hyperactivity of proteolytic MMPs

in the chronic wound environment (e.g. 65-fold higher levels of MMP1 in non-healing diabetic
foot ulcers compared to acute traumatic wounds (68)), which causes rapid degradation of new
granulation tissue and simultaneously degrades any exogenously applied VEGF. Therefore,
protection of VEGF and granulation tissue from proteolytic activity is necessary and can be done
by co-administration with MMP inhibitors, the use of ECM scaffolds as a competitive substrate,
and/or engineering of more cleavage-resistant VEGF mimics.
Another critical limitation is the maintenance of VEGF in its therapeutic range, which is
hindered by MMP-mediated degradation, its short half-life, and diffusion away from the site of
application into systemic circulation (95, 96). Furthermore, the potential for excessive VEGF
activation and systemic exposures raise concerns of uncontrolled angiogenesis forming
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hyperpermeable and tumor-like tortuous vasculature; this is a particular concern for applications
in diabetic patients, who are susceptible to excessive angiogenesis in the eye (diabetic
retinopathy) (97). These two interrelated problems illustrate the importance of controlling the
degree of VEGF activation and targeting VEGF therapies to limit systemic exposures. Recently,
researchers have improved therapeutic efficacy and prevented systemic exposure by modifying
VEGF with ECM-binding components to target VEGF activity in both diabetic wound healing
models and non-diabetic ischemic flap models (98-102).
Many growth factor therapies have shown measurable improvements in accelerating
diabetic wound closure in rodents but have failed to demonstrate sufficient efficacy in clinical
trials (103); currently, only PDGF (Becaplermin gel aka Regranex) has been FDA approved for
neuropathic DFU and is not appropriate for ischemic DFU, while development of topical VEGF
(Telbermin) for DFU was discontinued in 2008 during phase 2 clinical trials (103, 104). Failure
in clinical translation of growth factor therapies such as VEGF can be attributed, at least in part,
to failed maintenance in its therapeutic range due to growth factor degradation and diffusion
away from its targeted site (105, 106). Furthermore, these isolated growth factor therapies are
designed to address a singular defect and therefore do not account for multiple
pathophysiological deficiencies within the wound. Pro-angiogenic VEGF therapies for ischemic
DFU have shown encouraging success in rodent models but these current limitations contribute
to its failed translation into the clinic.

1.6

Our Approach to Improve VEGF Efficacy in the DFU Microenvironment
Development of effective therapies that can correct multiple derangements while

maintaining efficacy in the complex and highly proteolytic environment of the DFU has proven
exceptionally challenging. Currently, only modest benefits have been achieved by emerging
therapies targeting singular aspects of disease, and thus Futrega et al. argues that next-generation
DFU therapies should aim to combining growth factor, ECM scaffold, and cell treatments to
synergistically maximize repair potential in this complex environment (107). We thus focused
on treating multiple aspects of disease with a tiered approach, building in complexity, to induce
targeted and controlled angiogenesis through VEGF pathways, while bearing in mind important
design parameters of targeting, controlling, and protecting VEGF activity. Targeting and control
can be achieved by binding therapies to the wound bed and regulating VEGF release, while
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protecting VEGF activity was explored using two different mechanisms. First, collagen-targeted
nanoparticles loaded with VEGF could protect VEGF and maintain therapeutic concentrations
within the proteolytic wound environment, thereby prolonging treatment. Alternatively,
degradation-resistant peptides that activate and potentiate VEGF pathways could also be used to
prolong angiogenic activity. Furthermore, pro-angiogenic proteoglycans formed by the
combination of these peptides and proteoglycan mimics have the added capacity to protect ECM
from MMP degradation. Moreover, multiple bioactive peptides could be added to promote cell
recruitment by direct integrin-binding or chemotactic mechanisms. We thereby start discussing a
synthetic nanoparticle system to protect and deliver VEGF, and then propose two variants of proangiogenic decorin mimics that stimulate and potentiate VEGF angiogenesis, the last variant of
which also promotes endothelial progenitor cell recruitment. Both variants simultaneously
protecting existing ECM and/or exogenous ECM wound dressings from rapid degradation. Each
proposed therapy could be administered alone or in conjunction with one another to exploit
potentiation of VEGF. For example, a collagen scaffold-based delivery of a pro-angiogenic
decorin mimic coupled with controlled release of VEGF from a nanoparticle system will allow
potentiation of released VEGF, thereby reducing the necessary dose. We hypothesize that a
biomimetic collagen-binding peptidoglycan functionalized with a pro-angiogenic peptide will
protect the collagen matrix from rapid degradation, and also promote angiogenesis by
potentiating endogenous and exogenous VEGF to accelerate ischemic cutaneous wound healing.

1.7

1.7.1

SPECIFIC AIMS AND THESIS OVERVIEW: PROPOSED COLLAGEN-TARGETED
PRO-ANGIOGENIC THERAPIES
Aim 1. Develop a nanoparticle system for controlled release of VEGF
Our lab has developed thermosensitive nanoparticles to improve therapeutic efficacy of anti-

inflammatory peptides, delivered both intracellularly and extracellularly for various applications
ranging from decreasing intraarticular osteoarthritic inflammation (108-113) to reducing postangioplasty intimal inflammatory damage (114, 115). In Chapter 2 of this thesis, we first discuss
characterization and incremental improvements (greater therapeutic loading and prolonged release)
to the previously developed solid non-degradable nanoparticle systems and then demonstrate
proof-of-concept that these nanoparticle systems can be effectively adapted for extracellular
delivery of full length growth factors such as VEGF by employing collagen matrix targeting. The
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future vision for this therapeutic encompasses fully degradable, hollow, thermosensitive
nanoparticles conjugated with collagen-binding peptides for matrix targeting and a prolonged
release profile.
1.7.2

Aim 2. Synthesize and characterize pro-angiogenic decorin mimics
Our lab has pioneered a mimetic of decorin, a proteoglycan predominantly found in skin,

that binds specifically to collagen matrices and suppresses excess MMP-induced degradation of
collagen in an incisional wound environment (116). The decorin mimetic (DS-SILY), composed
of a dermatan sulfate (DS) backbone and a collagen-binding peptide (SILY), also decreases
dermal scarring by modulating collagen organization (116). Building upon this engineered
therapeutic technology, we propose to further functionalize our decorin mimetic with two
conjugated pro-angiogenic peptides, VEGF-mimicking “QK” and αvβ3 integrin-binding
“LXW7”, to stimulate angiogenesis through direct and indirect VEGF pathway activation,
respectively. Pro-angiogenic decorin mimics were synthesized with improved bioconjugation
chemistry with a degree of substitution of 4 collagen-binding peptides per dermatan sulfate
backbone, but modified with varying degrees of substitution of either the VEGF-mimicking
peptide “QK” or integrin-binding peptide “LXW7”. In Chapter 3, we discuss the synthetic
chemistry and post-conjugation peptide quantification. We also characterize the secondary
structure of pro-angiogenic peptides and matrix-binding capacity of pro-angiogenic decorin
mimics, as well as explore biological effects of the EDC synthetic chemistry on dermatan sulfate
and the decorin mimic DS-SILY through assessing endothelial cell (EC) proliferation and
VEGFR2 activation.
1.7.3

Aim 3. Assess in vitro and in vivo angiogenesis of pro-angiogenic decorin mimics

In Chapter 4, we quantify in vitro and in vivo angiogenesis, with and without VEGF, for the
two variants of pro-angiogenic decorin mimics by evaluating 1) EC proliferation and migration,
2) two-dimensional EC tubule formation on matrigel embedded with pro-angiogenic decorin
mimics, 3) neovascularization from a chick chorioallantoic membrane (CAM assay) growing into
a collagen scaffold embedded with pro-angiogenic decorin mimics, reflecting the ability of the
scaffold to integrate into existing vasculature, and 4) EC monolayer permeability.

11

2. DEVELOPMENT OF A DEGRADABLE, THERMOSENSITIVE
NANOPARTICLE SYSTEM FOR VEGF DELIVERY

2.1

Preface
The final pNIPAM nanoparticle drug delivery system that was tested for VEGF delivery

was a collaborative effort with Dr. Scott Poh and Dr. James McMasters and was the product of
incremental improvements, described over 3 published articles, outlining its efficacy in
delivering an anti-inflammatory peptide in osteoarthritic applications (111-113). The beginning
of this chapter therefore first addresses the osteoarthritis work to describe the improvements in
the nanoparticle system. Our lab more recently demonstrated that pNIPAM nanoparticles could
also deliver its payload extracellularly by implementing matrix-targeting through surface
modification with a collagen-binding peptide (114, 115). After illustrating the development of
our nanoparticle system through the aforementioned works, I describe the pilot experiments
showing translation to VEGF delivery.

2.2

Poly-N-isopropylacrylamide Nanoparticles for Drug Delivery
Numerous polymeric nanoparticles have been used to protect bioactive molecules until

release, ranging from naturally derived sources such as chitosan and alginate to synthetics such as
poly(caprolactone), poly(lactic-co-glycolic acid) (PLGA) and poly(N-isopropylacrylamide)
(pNIPAM). We have previously reported that peptide-loaded pNIPAm nanoparticles protect the
peptide therapeutic from enzymatic degradation, thus increasing drug half-life in the presence of
serum (109, 117). ‘Smart’ pH responsive or temperature sensitive polymers are particularly
advantageous because they can facilitate sustained controlled release that can be triggered by a
specific event. pNIPAM is one such stimuli-responsive polymer that undergoes a volume phase
transition at a lower critical solution temperature (LCST) between 31°C and 33°C (118, 119),
exhibiting a hydrophilic swollen state at low temperatures to a hydrophobic collapse at high
temperature in an aqueous environment. Due to this thermosensitive property, pNIPAM can be
passively loaded with water-soluble therapies in a cold expanded state and subsequently collapse
and entrap diffusible agents at physiological temperatures resulting in drug release over a
prolonged period of time (120).

pNIPAM’s ease of drug loading, biocompatibility, and
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physiologically relevant LCST independent of concentration and molecular weight make it a
highly attractive polymer for drug delivery, although co-polymerization of other monomers can
shift the LCST. One of the primary drawbacks of pNIPAM for targeted drug delivery is that its
narrow range of physical and chemical properties make it difficult to tune its intrinsic drug release
kinetics or directly add targeting moieties to its surface after synthesis. However, doping the
polymeric formulation with charged and/or chemically active co-monomers easily overcomes
these limitations. For example, previous work from our lab has demonstrated that incorporating a
modest 5 mol% of 2-acrylamido-2-methyl-1-propanesulfonic acid (AMPS), an anionic sulfated
monomer, into pNIPAM nanoparticles increased loading of cationic peptides and improved
colloidal stability (108, 109). Furthermore, co-polymerization with polyethyleneglycol (PEG) can
decrease non-specific protein binding (121), and endolytic degradation can be instilled using the
degradable crosslinker bis(acryloyl)cystamine (BAC) (113). Inclusion of acrylic acid imparts
chemical functionality of carboxylic acids that can be further reacted for surface modifications
(114, 115). Finally, the addition of fluorescent monomers such as fluorescein o-acrylate (113) or
methacryloxyethyl thiocarbamoyl rhodamine B (122) facilitates intracellular visualization.

13

2.3

A

Endolysosomal Intracellular Delivery of Anti-Inflammatory Peptides from PNIPAM
Nanoparticles with Reducible Crosslinks Decreases Inflammation in Cartilage Explants
Degradable, Redox-sensitive Nanoparticles (NGPEGSS)
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Figure 2-1. pNIPAM Nanoparticle Schematic.
(A) Degradable, redox-sensitive nanoparticles (NGPEGSS) were loaded with KAFAK and then taken up into the
cellular endolysosomal compartment, where they degraded and released KAFAK. (B) Non-degradable, hollow
nanoparticles (hNGPEGMBA) were developed from the nanoparticle platform shown in (A) by polymerizing a nondegradable shell around the reducible core, and then degrading and allowing the core to diffuse out by dialysis
before KAFAK loading.

2.3.1

Introduction
Osteoarthritis, affecting ~27 million Americans (123, 124), is the leading cause of

chronic disability in the United States (125). It is primarily characterized by a progressive cycle
of chronic inflammation (126) and cartilage degradation, causing joint pain and stiffness. In
response to sustained levels of pro-inflammatory cytokines, chondrocytes synthesize proteolytic
enzymes that degrade extracellular matrix components (127, 128), including aggrecan (129),
stimulating additional inflammation and facilitating penetration of inflammation and degradation
factors into the cartilage. Osteoarthritis is treated with anti-inflammatory therapies that provide
short-term relief and can have adverse side effects. Locally-delivered, degradable, controlled
release, anti-inflammatory drug delivery systems could prolong relief and minimize side effects.
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Brugnano et al. investigated an anti-inflammatory cell-penetrating peptide
KAFAKLAARLYRKALARQLGVAA, (KAFAK), which inhibits MAPK-activated protein
kinase 2 (MK2) (117). MK2 controls the synthesis of many pro-inflammatory cytokines,
including IL-1, TNF-α, and IL-6 (128, 130-132). The MK2 pathway is triggered in osteoarthritis
and promotes release of enzymes that degrade cartilage (128). KAFAK treatments are
susceptible to peptidases in the blood and synovial fluid. To limit systemic exposure and
premature degradation of KAFAK, our laboratory has designed polyN-isopropylacrylamide
(pNIPAM) nanoparticle delivery systems to increase the peptide’s therapeutic lifetime (108-110,
113, 133).
Bartlett et al. previously reported a thermosensitive non-degradable
methylenebisacrylamide (MBA) cross-linked pNIPAM-AMPS nanoparticle system for
delivering KAFAK in osteoarthritis applications (108). While Bartlett et al. also later reported
high pH sensitive, hydrolytically degrading above pH 5.0, pNIPAM nanoparticles with N,Odimethacryloylhydroxylamine (DMHA) crosslinks to deliver KAFAK to damaged cartilage, the
nanoparticles continuously degraded before reaching the target cell, thus limiting the therapeutic
potential of the system (110). Therefore, a nanoparticle that would not degrade until reaching the
target cell could improve targeted KAFAK delivery. To this end, we incorporated reducible
disulfide cross-links to the nanoparticle formulation using bis(acryloyl)cystamine (BAC,
represented by SS in nanoparticle nomenclature), and also added PEG2000 diacrylate to render
improved stability and ‘stealth’ properties and fluorescein o-acrylate for visualization. We
thereby developed a thermo- and redox-sensitive nanoparticle platform (referred to as
‘NGPEGSS’) that degrades in the low-pH and reducing environment of endolysosomes after
cellular uptake. When this reducible nanoparticle system was used to deliver KAFAK to RAW
264.7 macrophages, an approximately 6-fold greater KAFAK release and improved antiinflammatory response was seen compared to non-degradable NGPEGMBA counterparts (113).
As a step toward developing an improved KAFAK delivery system for osteoarthritis, we
investigated the ability of the NGPEGSS nanoparticles to selectively penetrate damaged
cartilage. We also investigated the ability of NGPEGSS, which show enhanced extracellular
stability and improved KAFAK retention and release, to effectively suppress inflammation via
chondrocyte uptake in an ex vivo model of osteoarthritis.
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2.3.2

Materials and Methods

2.3.2.1 Materials.
N-Isopropylacrylamide ( ≥ 98%, NIPAm) was acquired from Polysciences Inc.
(Warrington, PA, USA). Dialysis membrane tubing was purchased from Spectrum Laboratories
(Dominguez, CA). (1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (≥
98%, HBTU), N-hydroxybenzotriazole (> 97%, HOBT), N,N’-methylenebisacrylamide (99%,
MBA), sodium dodecyl sulfate (SDS; 10% w/v in water), 2- acrylamido-2-methyl-1propanesulfonic acid (99%, AMPSA), dithiothreitol (98%, DTT), fluorescein o-acrylate (98%,
F), N,N-Diisopropylethylamine (99%, DIPEA), potassium persulfate (99%, K2S2O8), N,N’bis(acryloyl)cystamine (98%, BAC), and dimethyl sulfoxide (DMSO) were acquired from
Sigma-Aldrich (St. Louis, MO, USA). NIPAm, MBA, and AMPS were stored under nitrogen at
4 °C. All water used in synthesis, dialysis, and testing was treated by a Milli-Q system
(Millipore, Billerica, MA, USA; 18.2 MΩ•cm resistivity). Acrylate-PEG2000 was purchased
from Laysan Bio (AL).
2.3.2.2 Peptide Synthesis and Purification
Therapeutic peptide KAFAK was synthesized on knorr resin by standard 9fluorenylmethyloxycarbonyl (Fmoc) solid phase methodology(113). Knorr amine resin was
swollen with dichloromethane (DCM) followed by dimethylformamide (DMF). A solution of
25% piperidine in DMF was added to the resin, bubbling under nitrogen for 15 min, and then
washed with DMF (3x) and isopropyl alcohol (i-PrOH, 3x). For amino acid coupling, a solution
of Fmoc-amino acid (3 equiv), (1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU, 3 equiv), N-hydroxybenzotriazole (HOBT, 3 equiv) and N,NDiisopropylethylamine (DIPEA, 5 equiv) in DMF was added to the resin bubbling under
nitrogen for 2 h, and then washed with DMF (3x), DCM (3x) and i-PrOH (3x). To deprotect
Fmoc, 25% piperidine in DMF was added to the resin, and nitrogen was bubbled for 20 min. The
solvent was then removed and the resin washed with DMF (3x) and i-PrOH (3x). The above
sequence was repeated for coupling and deprotection of each amino acid. The final compound
was cleaved from the resin with a cocktail of trifluoroacetic acid (Sigma-Aldrich, St. Louis, MO,
U.S.A.), triisopropyl silane (TCI America, Boston, MA, U.S.A.), ethane dithiol (Alfa Asara,
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Ward Hill, Massachusetts, U.S.A.), and Milli-Q water. The cleaved mixture was concentrated
under vacuum and then immediately precipitated in diethyl ether, recovered by centrifugation,
solubilized in Milli-Q water, and lyophilized (Supporting Scheme 1). Peptides were purified on
an FPLC AKTA Explorer (GE Healthcare, Pittsburgh, PA, U.S.A.) with a 22/250 C18 prep-scale
column (Grace Davidson, Deerfield, Illinois, U.S.A.) and an acetonitrile gradient with 0.1%
trifluoroacetic acid. Purity of peptides were determined by HPLC to be > 98%. Peptide
molecular weight was confirmed by matrix-assisted laser desorption ionization time-of-flight
(MALDI TOF) mass spectrometry with a 4800 Plus MALDI TOF/TOF Analyzer (Applied
Biosystems, Foster City, CA, U.S.A)(Supplemental Figure S1).
2.3.2.3 PNIPAM-AMPS Nanoparticle Synthesis
2.3.2.3.1 Solid Nanoparticles
Solid NIPAM-AMPS nanoparticles were synthesized similar to previous protocols.
Briefly, the nanoparticle compositions were formed by dissolving 192.1 mg NIPAM and 5 mol%
AMPS in 18 mL degassed MilliQ water in a three-neck round bottom flask. 3 mol% PEGacrylate and 2 mol% cross-linker (MBA, DMHA, or BAC) was pre-dissolved in 3% (v/v) of
dimethyl sulfoxide (DMSO) in water for 10 mins before addition to polymer mixture. 41 μL of a
10% (v/v) SDS in MilliQ water solution was added, and the mixture was heated to 65°C under
nitrogen. Potassium persulfate (8.4mg) was dissolved in 2 mL degassed MilliQ water and added
after a 35 mins equilibration to initiate polymerization. After 5 h, the reaction was removed from
heat and allowed to cool to room temperature. Particles were dialyzed against MilliQ water for 5
days using a 15,000 MWCO membrane.
For fluorescent nanoparticle synthesis, 1 mol% fluorescein o-acrylate (F) was predissolved in 3% DMSO solution. The dye-DMSO solution was added to the polymer mixture
and equilibrated for 30 mins. Potassium persulfate dissolved in 2 mL degassed MilliQ water was
added to initiate polymerization. Particles were dialyzed against MilliQ water for 5 days using a
15,000 MWCO membrane. All sample were freeze-dried and kept in the dark for further
experiments.
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2.3.2.3.2 Hollow Nanoparticles
We further used this degradable system to develop hollow nanoparticles by polymerizing
a non-degradable MBA cross-linked shell around a reducible disulfide cross-linked nanoparticle
core. For core synthesis, 49 mL of Milli-Q water was heated to 70oC in a 3-neck round bottom
flask and refluxed under nitrogen for 30 minutes. 178 mg of NIPAm, 6 mol% BAC, and 20 mg
of SDS were dissolved in 10 mL of degassed Milli-Q water and added to the flask. Finally, 35 mg
of potassium persulfate was dissolved in 1 mL of Milli-Q water and added to the flask to initiate
the reaction. The polymerization was carried out for 5 h under nitrogen. The resultant particles
were filtered through a Whatman filter to remove any aggregates, and then cleaned several times
by centrifugation and resuspension in Milli-Q water.
To create the non-degradable pNIPAM shell, 4 mg of SDS was added to 5 mL of the
disulfide crosslinked cores in a 3-neck round bottom flask and heated to 70°C under nitrogen. A
separate solution of 50 mg NIPAm, 5 mol% AMPSA, 2 mol% MBA and, for PEGylated
nanoparticles, 3 mol % Acrylate-PEG2000 were prepared in 30 mL of degassed Milli-Q water and
allowed to incubate to room temperature under nitrogen for 45 minutes before being added to the
heated core solution. To initiate polymerization, 6 mg of potassium persulfate was dissolved in 1
mL Milli-Q water and added to the flask. After 5 hours, the core-shell nanoparticles were collected
and dialyzed against Milli-Q water for 6 days using a 15 kDa MWCO dialysis membrane (SpectraPor).
Following dialysis, the core was degraded by re-suspending the core-shell particles in a 1
mM DTT solution and allowing the solution to react under stirring for 7 days. The hollow particles
were then cleaned by centrifugation and resuspension in Milli-Q water, frozen, and lyophilized.
For fluorescent nanoparticle synthesis, 1 mol% fluorescein o-acrylate was pre-dissolved in 3%
DMSO and then added to the shell polymer mixture and allowed to equilibrate for 30 minutes
before reaction initiation with the addition of potassium persulfate.
2.3.2.4 Nanoparticle Characterization
Size measurements were performed using dynamic light scattering (DLS) on a NanoZS90 Zetasizer (Malvern, Westborough, MA, USA). Zeta (ζ) potentials were measured at 25 °C
using a Nano-ZS90 Zetasizer in capillary cells in PBS. To characterize their degradation,
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samples with an identical particle concentration were prepared in pH 7.4 PBS buffer. To one
solution, an excess of DTT (1 mM) was added and allowed to incubate for 24 h.
2.3.2.5 Nanoparticle Drug Loading and Release
Purified peptide was first dissolved in ultrapure water to create a 5 mg/mL loading
solution, and then this solution was added to 5 mg of lyophilized nanoparticles and allowed to
incubate for 24 h at 4°C in the swollen state. After incubation, 9 mL of water was added and
particles underwent 1 h of centrifugation at 35,000 rpm and 37°C in an Optima L-90k
Ultracentrifuge (Beckman Coulter, Indianapolis, IN, USA). The nanoparticle pellet was briefly
re-suspended in 2 mL water and lyophilized. To collect peptide release profiles, KAFAK-loaded
nanoparticles were suspended in sterile PBS (Invitrogen, Grand Island, NY, USA) with or
without DTT over a 96 h period. Measurement of free peptide released into the solution and the
amount of peptide loaded were determined using fluorescence analysis with a fluoraldehyde
ophthalaldehyde (OPA) solution (Thermo Scientific, Waltham MA, USA) according to the
manufacturer’s protocol. For KAFAK release studies, fluorescent measurements of drug release
were taken every 15 min for the first hour and then at 1, 6, 12, and 24 h every day afterward for 4
days.
2.3.2.6 Chondrocyte Isolation and Culture
Primary chondrocytes were harvested from the load-bearing region of femoral condyles
from 3-month-old calves within 24 h of slaughter (Dutch Valley Veal, South Holland, IL, USA)
as described previously(110, 134, 135). Cells between passage 1 and 4 were seeded with 10,000
cells/well in 8-well Lab-Tek chamber slides for experiments.
2.3.2.7 Nanoparticle Uptake in Chondrocytes
To determine intracellular nanoparticle uptake, chondrocytes were incubated with 1.5
mg/mL fluorescein-labeled nanoparticles for 4 h or 24 h at 37°C in culture medium. All samples
were performed in triplicate. After washing with medium to remove any unbound nanoparticles,
the cells were imaged using confocal microscopy (Olympus FV1000). To analyze co-localization
of nanoparticles in endosomal/lysosomal compartments, Lysotracker DND-99 (Life
Technologies, Grand Island, NY, USA) staining was added according to the manufacturer’s

19
protocol. Semi-quantitative fluorescence measurements of confocal images were used to
compare uptake between degradable and non-degradable nanoparticles. Image analysis by
ImageJ determined the number of fluorescent pixels (area) and the integrated fluorescence
intensity for the green channel normalized to the red channel within each field of view (n = 3).
Overlapping green and red fluorescence indicated co-localization of green nanoparticles inside
red endolysosomes.
Cell samples were subjected to the trypan blue dye exclusion to evaluate cell viability,
and CellTiter 96 AQueous One Proliferation Assays (Promega, Madison, WI, USA) were
performed on chondrocytes according to the manufacturer’s protocol to quantify nanoparticle
cytotoxicity.
2.3.2.8 Ex vivo Osteoarthritis Model
Cartilage plugs (3mm diameter isolated as described above) were washed three times in
serum-free medium and equilibrated for 3 days in 5% FBS supplemented media. Osteoarthritis
conditions were simulated by removal of native aggrecan and then inducing inflammation using
a previously described protocol (135). After culturing for 2 days, nanoparticle treatments were
added. Fresh IL-1β and nanoparticles were added every 2 days for an 8-day culture period.
Media aliquots were collected and stored in low bind tubes at -80°C until further analysis.
2.3.2.9 Analysis of ex vivo IL-6 Secretion
IL-6 cytokine production from cartilage plugs was determined with a bovine IL-6 ELISA
development kit (PIESS0029, Thermo Scientific, Rockford, IL, USA) according to the
manufacturer’s protocol. IL-6 production was normalized to individual plug weight and to the
negative control where healthy plugs with intact aggrecan were IL-1β stimulated.
2.3.2.10 Cartilage Penetration by Nanoparticles
Bovine cartilage plugs were either trypsin treated to simulate osteoarthritis-like
conditions or left in cell culture media to maintain healthy tissue-like environment. Nonfluorescent nanoparticles (as control) and fluorescent nanoparticles were re-suspended at 0.5
mg/mL in PBS and added to cartilage plugs for 24 h. After treatment, plugs were washed 3 times
with PBS and incubated at 37°C for 30 mins to remove any unbound nanoparticles. A midsagittal cut (30 µm thickness) was made through the plug using a cryotome. Sections were
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imaged by confocal microscopy at 488 nm excitation (Olympus FV1000) to examine the depth
of fluorescent nanoparticle penetration into the plugs from the articular surface. Fluorescent
intensity was quantified using ImageJ, and the intensity in three independent areas near the
articular surface of each image was measured with values represented as average intensity ±
SEM.
2.3.2.11 Statistical Analysis
Student’s t-tests were used to determine statistical significance between treatment groups
(α = 0.05). Data is expressed as mean values ± standard deviation unless otherwise noted.
2.3.3

Results

2.3.3.1 Nanoparticle Characterization
Previous work from our laboratory showed that 5% AMPS co-monomer in pNIPAM
nanoparticles resulted in maximum KAFAK loading capacity (108). Incorporating 5% AMPS
into disulfide PEGylated (NGPEGSS) nanoparticles yielded loading efficiency of 34.6%, which
was statistically equivalent to non-degradable PEGylated nanoparticles (NGPEGMBA) at 36.7%
and high-pH degradable NGPEGDMHA nanoparticles at 34.7% (Table 2-1). In contrast, hollow
non-degradable nanoparticles exhibited a significantly increased loading efficiency of 49.8%.
All nanoparticles also possess a negative ζ potential as expected due to the incorporation of the
sulfated AMPS, although the range of ζ potentials did not vary much among the different
nanoparticle formulations. Therefore, changing cross-link type does not have a profound impact
on ζ potential for particles when using 2 mol% cross-linker content as shown in Table 2-1.
Table 2-1. Size, ζ Potential, and Drug Loading
Size measurements reported here were determined by DLS at ambient temperature in PBS at 25°C and 37°C.
Percent drug loading is defined as the mass of KAFAK encapsulated within a given mass of nanoparticles. Zeta
potential measurements are provided for nanoparticles in ultrapure water and PBS at room temperature to reflect
nanoparticle properties during drug loading and in physiologically relevant solutions, respectively.
Nanoparticle

Size25°C (nm) ±
stdev

Size37°C (nm)
± stdev

Drug loading
(%) ± stdev

Zeta potentialH2O
(mV) ± stdev

Zeta potentialPBS
(mV) ± stdev

NGPEGMBA
NGPEGDMHA
NGPEGSS

246 ± 8.9
237 ± 8.2
223 ± 9.7

235 ± 1.5
213 ± 1.8
207 ± 5.0

36.7 ± 4.3
34.7 ± 7.2
34.6 ± 3.7

-11.3 ± 1.34
-19.1 ± 1.91
-19.9 ± 2.16

-4.28 ± 1.56
-6.05 ± 1.91
-3.81 ± 2.01

hNGPEGMBA

311 ± 9.3

192 ± 13.3

49.8 ± 8.7

No data

-8.48 ± 3.50
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DLS size measurements over a 20°C to 50°C temperature sweep demonstrated that the
ability of pNIPAM-AMPS nanoparticles to collapse in response to increasing temperature was
maintained with the incorporation of PEG and disulfide cross-links (Table 2-1 and Figure 2-2A).
We found that while AMPS addition shifted the LCST to a higher temperature of ~38°C (Figure
2-2A) compared to pure pNIPAM, addition of PEG to the bulk nanoparticle formulation did not
affect the LCST (data not shown). The LCST shift with AMPS addition is supported by Bartlett
et al.’s observation that increasing AMPS content caused a corresponding shift in LCST to
higher temperatures (108). LCSTs of nanoparticles with disulfide versus MBA crosslinks are
similar, indicating that the change in crosslink type did not significantly affect LCST. Figure 22D also shows that hollow non-degradable nanoparticles (hNGPEGMBA) were significantly
larger in the expanded state, as expected due to polymerization around a similarly sized core, but
also collapsed more at high temperatures than solid non-degradable counterparts. The
hNGPEGMBA nanoparticles displayed a ~38% decrease in size from 25°C to 37°C compared to
~4.5% decrease for their solid NGPEGMBA counterparts.
Figure 2-2B demonstrates a progressive decline in NGPEGSS nanoparticle size over time
(~30% decrease in diameter) indicating slow nanoparticle degradation over 48 hours when
exposed to reducing conditions, whereas NGPEGMBA and NGPEGDMHA did not exhibit a
drastic change in size (~4% decrease). Non-degradable nanoparticles did not significantly change
in size or drug release over time in either pH 7.4 or pH 4.0 environments (Figure 2-2 B & C),
while degradable disulfide cross-linked nanoparticles (NGSS and NGPEGSS) decreased in size
corresponding to a significant increase in drug release after addition of DTT (Figure 2-2 B & C)
and similar results were also seen at pH 4.0 (113). Figure 2-2B also shows that NGPEGDMHA
nanoparticles degraded readily at physiological pH of 7.4 over time.

22

B

Thermosensitive Nanoparticle Collapse

E
.S

S
~

"'

i5

Nanoparticle Degradation Over Time
PBS(pH 7.4)

280
260
240
220
200
180
160
140

+DTT

280

1220
i; 200

._! 200

E1so

E18o

5 160

i5 160

140

140

NGPEGSS
120
100+----~--------~
20
30
40
50

+

120
100

0

IIGPE(J,16A

~

IIGPEGSS

20

10

+ NGPEGOUHA

..

30

Time (hr)

Temperature (°C)

C

120

... NGPEGMBA

+

10

20

50

0

Degradable

Non-degradable

-

NGMBA pH 7.4
NGPEGMBA pH 7.4

-

-

NGMBApH4.0
NGPEGMBA pH 4.0

+DTT

~

::

"'20

I

"

"
0

0

24

48

72

96

Time (hr)

•

+ NGPEGSS (OTT)

11

,5

e

... NGPEGSS, pH7.4

tGSS (DTT)

30

!2

E

50

40

,,;

Non-degradable
Solid vs. Hollow

40

30

- - l'l,SS, pH 7.4

600

MGPEGl».1HA

Time (hr)

40

D

+

MGPEGSS

100

10

pH 7.4
0

0

24

48

72

96

Time (hr)

Non-degradable

Solid vs. Hollow
NGPEGMBA

+ hNGPEGMBA

400

-=~

... ~ G MBA

GI

t

..

-

E
i5

30

40

Temperature (0 C)

NGPEGMOA

50

Time (hr)

Figure 2-2. Nanoparticle Characterization by Size and Drug Release.
DLS size measurements are shown as a function of temperature (A & D) and as a function of time in PBS and upon
addition of DTT (B & C). Hollow non-degradable nanoparticles (hNGPEGMBA) were significantly larger in the
expanded state and collapsed more at high temperatures than solid non-degradable counterparts (D). Nondegradable nanoparticles do not have a significant change in size or drug release over time in either pH 7.4 or pH 4.0
environments, while degradable disulfide cross-linked nanoparticles (NGSS and NGPEGSS) demonstrate a
significant decrease in size corresponding to a significant increase in drug release after addition of DTT (B & C).
Hollow non-degradable nanoparticles exhibited the greatest drug release over time (E), exhibiting an improvement
over solid degradable nanoparticles in a reducing environment. Sample size n = 3 for all nanoparticle
measurements.

2.3.3.2 Chondrocyte Nanoparticle Uptake and Cytotoxicity
Confocal microscopy confirmed the uptake of both fluorescent degradable NGPEGSSF
and non-degradable NGPEGMBAF nanoparticles into primary chondrocytes after 24 h
incubation but not after 4 h incubation (Figure 2-3). Figure 2-3 also demonstrates co-localization

of green fluorescent nanoparticles with red endolysosomal compartments for both MBA and
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BAC crosslinked nanoparticles. Semi-quantitative green/red fluorescence ratio analysis in Figure
2-4, where green/red pixel area ratio of 1.0 represents 100% co-localization of particles with
endolysosomes, suggests that green/red pixel area is statistically similar between the two types of
nanoparticles. However, the green/red integrated intensity ratio is significantly greater for the
NGPEGSS as compared to the NGPEGMBA nanoparticles suggesting that the total number of
nanoparticles taken up into these intracellular compartments is higher for NGPEGSS than
NGPEGMBA. The CellTiter assay showed no significant cytotoxicity after incubation for 48 h
with NGPEGSS, NGPEGMA, or free KAFAK peptide (Figure 2-5).

(A) non-fluorescent nanoparticles as negative controls; (B&C) fluorescent nanoparticles after (B) 4 h and (C) 24 h
incubation; (D) Lysotracker DND-99; (E) green nanoparticle overlay on red endolysosomes.

Figure 2-3. Confocal microscopy of primary bovine chondrocytes incubated at 37°C with (1) NGPEGMBA
and (2) NGPEGSS.
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2.3.3.3 Cartilage Penetration by Nanoparticles
Incubation of cartilage explants for 24 h with FITC-labeled nanoparticles revealed greater
penetration of nanoparticles throughout inflamed, aggrecan-depleted cartilage plugs compared to
their healthy counterparts (Figures 2-6).
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Figure 2-6. Mid-sagittal cross-sections of bovine knee explants from the load-bearing region of the femoral
condyles.
The interface represents the articular surface after 24 h incubation with FITC-labeled nanoparticles; (Top)
NGPEGSSF and (Bottom) NGPEGMBAF. Left panel represents normal healthy cartilage incubated with fluorescent
(A) NGPEGSSF or (C) NGPEGMBAF showing minimal diffusion of fluorescent particles. Right panel represents
(B) NGPEGSSF and (D) NGPEGMBAF diffusing through the inflamed, aggrecan-depleted ex vivo cartilage
explants. Scale bar represents 100 μm. (E) Average intensity analysis of the articular surface incubated with
fluorescent nanoparticles. Significantly higher fluorescence is observed in inflamed, aggrecan-depleted cartilage
(Trypsin + IL-1β) demonstrating greater penetration of nanoparticles. Significance denoted as ** with p < 0.01. Bars
represent intensity averages ± SEM of 3 independent areas at the articular surface.

2.3.3.4 IL-6 Expression in Cartilage Explants Treated with KAFAK-loaded Nanoparticles
Inflamed, aggrecan-depleted cartilage explants treated with either KAFAK-loaded
NGPEGSS or KAFAK-loaded solid or hollow NGPEGMBA exhibited significant suppression of
IL-6 secretion on days 4, 6, and 8 (Figure 2-7 E, G, & I). Furthermore, NGPEGSS decreased IL6 production by a greater degree compared to NGPEGMBA on days 6 and 8. In comparison to
solid non-degradable nanoparticles, KAFAK-loaded hollow non-degradable hNGPEGMBA also
provided greater IL-6 suppression continuing through day 8 (Figure 2-7 I). These antiinflammatory effects can be ascribed to KAFAK released from the nanoparticles, as the empty
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nanoparticles do not suppress IL-6 secretion (Figure 2-7 D, F, & H). As demonstrated by Figure
2-7C, free KAFAK treatment was not effective in inflammatory suppression presumably due to
rapid degradation by peptidases present in serum-supplemented media.
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Figure 2-7. Normalized IL-6 production by IL-1β inflamed, aggrecan-depleted cartilage plugs dosed with
nanoparticles loaded with and without KAFAK.
Treatments were added on day 2 after IL-1β stimulation. (A) Negative control, healthy cartilage without IL-1β
stimulation. (B-E) Aggrecan-depleted plugs dosed with IL-1β and treated with (B) PBS, (C) free KAFAK, (D)
empty NGPEGSS, (E) KAFAK-loaded NGPEGSS, (F) empty NGPEGMBA, (G) KAFAK-loaded NGPEGMBA
nanoparticles, (H) empty hNGPEGMBA, (I) KAFAK-loaded hNGPEGMBA. Plots are normalized to individual
plug weight and IL-6 production from the control and represent average ± SEM (n = 3). * denotes p < 0.05 and ** p
< 0.01 with respect to the IL-1β positive control (plot B). + denotes a significant difference (p < 0.05) in IL-6
production between KAFAK-loaded NGPEGSS and NGPEGMBA nanoparticles on days 6 and 8.
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2.3.4

Discussion & Conclusions
To develop a clinically relevant nanoparticle therapy for intra-articular injection to treat

osteoarthritis, it is imperative that the nanoparticles do not aggregate in aqueous solutions and
effectively deliver their payload to the target cells. With respect to nanoparticle stability,
negative surface charge (ζ potential) can prevent aggregation and was achieved in all
nanoparticle formulations explored here through the addition of 5% AMPS. As described
previously, in aqueous solutions pNIPAM nanoparticles with 5% AMPS co-monomer remain
spherical, well dispersed, and capable of delivering therapeutic peptides (109, 113). KAFAKloaded pNIPAM nanoparticles with N,O-dimethacryloyl hydroxylamine (DMHA) crosslinks
were reported to impart anti-inflammatory activity in cartilage explants and to penetrate deeply
into aggrecan-depleted cartilage (110). However, the extracellular instability of the DMHAcrosslinked nanoparticles resulted in rapid release of KAFAK and may not efficiently protect the
KAFAK from extracellular proteases. In contrast NGPEGSS nanoparticles were stable and
released less than 10% of the loaded KAFAK over 96 h at pH 7.4, but released up to ~30% of
loaded KAFAK within the same 96 h period in a reducing environment (shown by both DTT and
pH 4.0 degradation studies) where the particles exhibited a significant decrease in size (113). In
this study, we demonstrated that NGPEGSS nanoparticles were more effective at delivering
KAFAK and produced an enhanced anti-inflammatory response in cartilage explants compared
to non-degradable particles with prolonged efficacy lasting up to 8 days in response to bolus
nanoparticle treatments every 2 days (Figure 2-7). Although we did not directly compare antiinflammatory efficacy of KAFAK-loaded NGPEGSS to NGPEGDMHA in this study, it is likely
that limiting extracellular KAFAK release would improve payload delivery by protecting
KAFAK from proteases within synovial fluid.
Investigation of peptide loading into hollow non-degradable nanoparticles demonstrated
loading efficiencies of ~49%, significantly higher than those found in their solid non-degradable
counterparts which remained ~35%. In this follow-up study developing hollow non-degradable
nanoparticles, we found that the new larger, more collapsible, and less dense system was able to
achieve both higher loading and greater release than the aforementioned reducible NGPEGSS,
and also provided extended IL-6 inflammatory suppression in the ex vivo cartilage explants. The
main drawback was that the non-degradable hollow nanoparticles still only achieved maximum
release of up to ~50% of the initially loaded peptide. We note that even in the degradable solid
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NGPEGSS system, only ~30% of loaded peptide was freed from the particles and thus some
amount may always be physically associated with the particle. Future nanoparticle formulations
thus focus on creating hollow nanoparticle platforms that could additionally incorporate a
triggered degradation after administration in hopes of maximizing peptide release.
Previous studies exploring efficacy of the NGPEGSS nanoparticle system for treatment
of osteoarthritis confirmed uptake into macrophages (113), but did not investigate cartilage
penetration nor uptake into chondrocytes. In studies presented here, as expected based on
chondrocyte uptake of other nanoparticle carriers (chitosan (136), iron oxide (137, 138), and
PLGA (139)) ranging from 50 nm to 300 nm, we observed nanoparticle uptake into
endolysosomal compartments within chondrocytes (Figures 2-1 & 2-2). Additionally, we
observed reduced chondrocyte expression of inflammatory cytokines upon uptake of KAFAKloaded nanoparticles. Importantly for treatment of osteoarthritis, these nanoparticles reduce proinflammatory cytokine expression in macrophages (113) as well as chondrocytes. This suggests
that our sulfated pNIPAM nanoparticle system penetrates inflamed cartilage and then gets taken
up by both macrophages, which have evolved to endocytose foreign objects, and the
chondrocytes present within the cartilage. Therefore this delivery system shows significant
promise for treatment of articular cartilage via intraarticular injection.
While the disulfide crosslinked nanoparticles exhibit the majority of their KAFAK
release within 48 h of encountering a degradation stimulus, they remain stable and release less
than 10% of the loaded peptide prior to entering endolysosome environments (113). Further, they
significantly prolonged suppression of the secretion of IL-6 by inflamed, aggrecan-depleted
cartilage. Similarly, hollow non-degradable nanoparticles also exhibit the majority of their
KAFAK release within 48 h; however this release begins as soon as the nanoparticles are
administered. The benefit of the hollow non-degradable nanoparticles is mainly due to their
increased loading and total release. Although we only demonstrated the ability of solid
nanoparticles to be taken up into chondrocytes, we expect that the hollow nanoparticles
discussed here would also have a similar property since the increased particle size is still within
the range of reported particles taken up by chondrocytes in literature. The ability of our reported
nanoparticles to diffuse into damaged cartilage, get taken up by chondrocytes and macrophages,
and maintain the majority of their payload prior to cell uptake (for NGPEGSS) may make these
systems ideal for treatment of osteoarthritis.
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2.3.5

Towards a VEGF-delivery system
The main takeaways from this work towards an effective VEGF-delivery system was the

method for adding redox-sensitive, low pH-triggered degradation in addition to our previously
developed high pH (> 5.0) degrading DMHA cross-linked platform, and the implications for pHtriggered VEGF release in the wound environment. Although investigations of the role of pH in
wound healing has been largely neglected and poorly understood in recent literature, pH has a
key regulatory role in metabolic activity within a healing wound (140). While skin pH between
4-6 is known to be an indicator of healthy skin barrier function (141), chronic wounds are
characterized by a significantly alkaline environment (142, 143). Schneider et al.’s review on
the influence of pH on wound healing concludes that targeted titration of the wound pH back to
an acidic milieu restores self-healing properties through inhibition of bacterial growth and
promotion of fibroblast proliferation and re-epithelialization. Furthermore, physiological
acidosis also significantly inhibits MMP activities, as optimal pH for these proteases has been
reported ~pH 8.0 (140). Therefore, acidifying the wound environment at the time of nanoparticle
application would be beneficial on multiple counts, in addition to triggering VEGF release from
disulfide crosslinked nanoparticles. Alternatively, using previously developed DMHA crosslinks could allow rapid VEGF delivery within the alkaline chronic wound environment. Another
promising method of promoting nanoparticle degradation in the wound environment would be
the use of MMP-degradable peptide-based cross-linkers.
The described reducible nanoparticles could be passively loaded with VEGF at cold
temperatures and exhibit minimal release at physiological temperatures until reaching low-pH or
reducing environments. We further demonstrated nanoparticle colloidal stability with the tested
formulation and that its size at ~207 nm at physiological temperatures results in nanoparticle
uptake by non-phagocytic cells such as chondrocytes. This finding highlighted the importance of
extracellular tethering for small nanoparticles to ensure extracellular payload release. To this
end, McMasters et al.’s surface addition of a collagen-targeting peptide tethering pNIPAM
nanoparticles to secreted collagen outlines a method of preventing cellular uptake (115).
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2.4

2.4.1

Pilot Studies for VEGF Loading and Release from Hollow Thermosensitive
Nanoparticles
Materials and Methods

2.4.1.1 Materials
VEGF-165 (carrier-free) and VEGF ELISA duoset was purchased from R&D systems.
All other materials for nanoparticle synthesis were the same as those reported in previous
sections.
2.4.1.2 Hollow Nanoparticle Synthesis
Hollow nanoparticles were synthesized with slight modifications to previously reported
methods (112). Uncrosslinked cores, held together by hydrophobic interactions, were first
formulated. Shells, including 1 mol% acrylic acid and 50% increased potassium persulfate
initiator but without PEG2000 diacrylate, were then polymerized around them as previously
reported. The core-shell construct was then dialyzed against water in an expanded state over 7
days at 4°C to allow for dissolution of the core through the shell.
2.4.1.3 Nanoparticle Size Characterization
Size measurements were performed using dynamic light scattering (DLS) on a NanoZS90 Zetasizer (Malvern, Westborough, MA, USA).
2.4.1.4 Conjugation of Collagen-binding Peptide to Nanoparticles
SILY, with a C-terminal ‘GC’ dipeptide modification (RRANAALKAGELYKSILYGC),
was custom synthesized by GenScript and received at 80% purity. This collagen-binding peptide
was covalently conjugated to hollow nanoparticles with a previously reported method (114, 115).
Briefly, 20 mg of nanoparticles containing 1 mol % acrylic acid were suspended at 1 mg/mL in
pH 6.0 coupling buffer consisting of 0.1M MES, 500 mM NaCl. EDC and sulfo-NHS were
added to final concentrations of 0.4 mg/mL and 1.1 mg/mL, respectively, for 15 minutes to
activate carboxylic acids. 1 molar equivalent of N-β-Maleimidopropionic acid hydrazide
(BMPH) for each mole of acrylic acid was added to react for 30 minutes at room temperature.
The solution was then centrifuged and supernatant removed. The nanoparticle pellet was washed
with water and centrifuged sequentially 3 times and then lyophilized. The maleimide group of
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the surface functionalized BMPH was then reacted with the free thiol of the C-terminal cysteine
of the collagen binding peptide in 1 molar excess to ensure complete reaction with BMPH.
Modified nanoparticles were then washed and centrifuged sequentially 3 times to remove excess
reactants, and lyophilized.
2.4.1.5 Nanoparticle Drug Loading and Release
Carrier-free VEGF-165 was first dissolved in ultrapure water to create a 1 µg/mL loading
solution, and then lyophilized nanoparticles were suspended in loading solution at a final
concentration of 1 mg/mL and allowed to incubate for 24 h at 4°C in the swollen state. After
incubation, particles were centrifuged for 45 minutes at 18,000g and 37°C. The supernatant was
collected and centrifuged through a 100,000 MWCO NanoSep centrifugal filter to remove any
residual nanoparticles. Supernatant was used to determine loading efficiency, and the
nanoparticle pellet was resuspended briefly in 250 µL water before lyophilization. To assess
peptide release profiles, VEGF-loaded nanoparticles were resuspended in 1 mL 37°C PBS and
kept shaking in a heated plate shaker. At each time point, the loaded nanoparticles were
centrifuged through a 100,000 MWCO NanoSep centrifugal filter for 45 minutes and filtrate
removed for each time point. Another 1 mL of warmed PBS was then added to re-suspend the
particles and continue VEGF release. For release studies, samples of drug release were taken at
3, 6, 12, and 24 h. Measurement of VEGF loaded and released into the solution were determined
using VEGF-165 ELISA (R & D systems) according to the manufacturer’s protocol. Solutions
were diluted 100-fold to obtain readings within the detection range. It was critical that all
solutions were centrifuged through the 100,000 MWCO NanoSep centrifugal filter prior to
ELISA since it was found that residual nanoparticles (and their associated VEGF) interfered with
ELISA VEGF detection and could cause artificially increased measurements.
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2.4.2

Results

2.4.2.1 Nanoparticle Size Characterization
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Figure 2-8. DLS Size Characterization of Non-degradable Hollow Nanoparticles, synthesized by diffusion of
an uncrosslinked core, as a function of temperature. Sample n = 3. Error bars are too short to be seen.
Non-degradable hollow pNIPAM nanoparticles exhibit an LCST of ~28°C.

Hollow nanoparticles synthesized by this alternate method using an uncrosslinked core
were ~450 nm at 25°C and ~345 nm at 37°C, and exhibited an LCST at ~28°C. It appears that
hollow nanoparticles exhibit a significantly lower LCST than solid nanoparticles, perhaps due to
a lower particle polymer density leading to less hindered collapse.
2.4.2.2 VEGF Loading and Release
The post-loading supernatant solution revealed remarkably low residual VEGF at ~50
ng/mL resulting in a loading efficiency of 94.8 ± 0.33%, totaling ~0.95 µg VEGF loaded per mg
of nanoparticles. However, only 4.9 ± 1.1% of the loaded VEGF, totaling ~47 ng VEGF per mg
of loaded nanoparticles, was released over a 72 hour period at 37°C (Figure 2-9B). At the 0.6
mg/mL nanoparticle solution tested, this amounted to ~25 ng/mL released VEGF in solution over
72 hours with release rates ranging from 0.55 ng/mL to 3.4 ng/mL per hour during hours 3-12
(Figure 2-9 A & B). The loaded nanoparticles only exhibit significant VEGF release within the
first 12 hours, while the remaining loaded VEGF appears to stay entrapped.
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2.4.3

Discussion and Future Directions

This study demonstrated that hollow non-degradable nanoparticles could be synthesized
using an uncrosslinked core, in comparison to the reducible disulfide crosslinked core that we
previously reported (112). With this development, we could make the hollow nanoparticles
degradable in future studies by using either the BAC or DMHA crosslinks. Given that high
loading efficiencies (~95%) were achieved, the main barrier in the use of this system for VEGF
delivery is the low percentage of VEGF release (~5%) and that VEGF only appears to release at
significant levels for the first 12 hours. Future studies could also investigate whether loading
efficiency is dependent on the concentration of the loading solution, and whether the release
profile is dependent on the initial load amount. Although the total amount of VEGF released is
low, the achieved ranges of 1-10 ng/mL concentrations of VEGF is optimal for stimulating
endothelial cells. Future studies focusing on building in controlled release of the remaining
VEGF will be important to ensure slow sustained levels of VEGF within the wound
environment. This is especially critical since a large proportion of VEGF remained inaccessible
and associated with the particles, and the effects of nanoparticles with tightly bound residual
VEGF on tissue is unknown.
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3. SYNTHESIS AND CHARACTERIZATION OF PRO-ANGIOGENIC
DECORIN MIMICS

3.1

Preface
In this chapter, we focus on the design, synthesis, and chemical/structural characterization

of pro-angiogenic peptides and 2 variants of engineered pro-angiogenic decorin mimics. A
number of significant developments and discoveries were made in the synthetic chemistry and
post-conjugation peptide quantification. First, we report bioconjugate chemistry using a one-step
EDC reaction of peptide hydrazides, synthesized in house, with carboxylic acid moieties on
glycosaminoglycans, which has only recently been described for synthesis of proteoglycan
mimics. In determining peptide substitution post-conjugation, multiple methods of peptide
quantification were explored and we report two high-throughput, non-destructive methods of
final peptide substitution quantification. After describing the development of synthetic methods
of peptides and decorin mimics, we discuss structural characterization of peptides and peptide
conjugates, VEGF receptor binding properties of the VEGF-mimicking peptide ‘QK’, and
protein-coated surface-binding properties of pro-angiogenic decorin mimics. Studies revealed
chemical and structural changes to the glycosaminoglycans caused by the EDC reaction, and we
subsequently report pilot studies exploring the biological ramifications of these changes through
studying changes in VEGF receptor 2 activation. In response to these findings, we also discuss
preliminary progress towards changing the synthetic chemistry to replace EDC with DMTMM to
activate carboxylic acid groups. A design schematic of the proposed pro-angiogenic decorin
mimics is depicted in Figure 3-1, and an outline of the breakdown of topics discussed is
diagrammed in Figure 3-2.
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3.2
3.2.1

Introduction
Proposed Pro-Angiogenic Decorin Mimics
Decorin is a small leucine-rich proteoglycan found abundantly in skin involved in

maintaining regularity in collagen fibrillogenesis (144-146) and preventing hypertrophic scars
(147). It is composed of a collagen-binding protein core attached to a dermatan sulfate (DS) side
chain (116). Our lab has developed a decorin biomimetic termed DS-SILY, composed of a short
collagen-binding peptide (“SILY”, designed from the collagen-binding receptor on platelets
(148)) conjugated to a DS backbone. Similar to the functions of decorin, DS-SILY has been
shown to bind and modulate collagen fibril formation and organization, suppress excess MMP
degradation of collagen, improve wound strength, and decrease scar formation by modulating
collagen organization in an incisional wound environment (116). Building on this engineered
therapeutic technology as a platform for tethering bioactive peptides to the DS backbone, we
explored the ability of 2 different conjugated pro-angiogenic peptides, VEGF-mimicking “QK”
and αvβ3 integrin-binding “LXW7”, to stimulate angiogenesis through direct and indirect VEGF
pathway activation, respectively. The benefits of this therapeutic design are several-fold. As
previously stated, the decorin mimetic would protect native or exogenous collagen from rapid
proteolytic degradation. Additionally, the use of synthetic pro-angiogenic peptides provides a
scalable means of stimulating VEGF-like activity with less susceptibility to proteolytic
degradation by way of reduced proteolytic sites and/or incorporation of unnatural amino acids
(149, 150). Angiogenic activity would be bound to collagen in the wound bed which would limit
systemic exposure, increase the local concentration of the angiogenic molecule, and mimic
matrix-bound presentation of VEGF. This tethering of VEGF to the wound bed has been shown
to be superior to free VEGF in diabetic wound models (100). Our proposed platform therefore
creates a functional bioactive interface mimicking native extracellular matrix (ECM), which
could exploit the important ECM-growth factor interactions known to regulate and potentiate
growth factor activities (151-154). For instance, VEGF released from alginate beads has been
shown to be 4 times more potent than an equivalent mass of VEGF (155), collagen matrix-bound
VEGF has been shown to mediate sustained VEGFR2 internalization and clustering, leading to
prolonged activation kinetics of the VEGF pathway (156), and heparin/heparan sulfate have been
found to act as a co-receptor for VEGF activation in a synergistic manner (157, 158). Therefore
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our glycosaminoglycan-based therapy may interact with and potentiate endogenous or exogenous
FGF and/or VEGF, while simultaneously presenting its own enhanced angiogenic stimulus.
Finally, the fact that dermatan sulfate is released at high concentrations in the proliferative phase
of wound healing implicates its important role as a cofactor in orchestrating wound repair (153).
3.2.2

Pro-angiogenic Peptides Activating VEGF Pathways

3.2.2.1 VEGF-mimicking Peptide “QK”
VEGF-mimicking peptide “QK”, developed by D’Andrea et al., is a 15 amino acid
sequence (KLTWQELYQLKYKGI) representing the receptor-binding region of VEGF modified
to maintain alpha helical secondary structure and VEGF bioactivity (159, 160). It has been shown
to bind and induce dimerization of VEGF receptors, upregulate VEGF receptor expression,
potentiate VEGF activity, and stimulate endothelial proliferation, migration, and network
formation on matrigel, and induce angiogenic sprouting from ex vivo vessels (159, 160). In vivo,
QK has been shown to stimulate vasodilation and neovascularization similar to VEGF in ischemic
hind-limb, excisional wound healing, and matrigel plug angiogenic models (161). In the woundhealing model, QK applied directly to 20 mm diameter full-thickness excisional wounds
accelerated wound closure to the same degree as VEGF therapy compared to controls. While QK
has not been studied specifically on ischemic dermal wounds, exogenous VEGF therapy has been
shown to improve survival of ischemic skin flaps on Sprague Dawley rats (94).
Although these studies demonstrate the promise of QK free-peptide, further studies suggest
that immobilization of the peptide to a substrate preserves angiogenic properties and may even
provide enhanced bioactivity, similar to previously noted matrix-interaction synergy with VEGF.
Researchers have investigated the angiogenic activity both in vitro and in vivo of tethered QK to
extracellular matrices, PEGDA hydrogels, or self-assembling nanofibers (162-165).

Recent

studies have shown increased endothelial tubule formation after “click” conjugation of QK to
decellularized ECM (162), increased VEGF pathway activation and sprout formation by a
collagen-binding QK peptide on collagen-coated surfaces and collagen gels (165), enhanced
2D/3D tubulogenesis and mouse corneal micropocket angiogenesis by QK conjugation to PEGDA
hydrogels compared to QK alone (163), enhanced endothelial proliferation and outgrowth from
encapsulated HUVEC spheroids in elastin-like polypeptide hydrogels with immobilized QK
compared to free QK (166), and increased microcirculation and alleviation of hind-limb ischemia
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in a mouse model by QK conjugation to self-assembling nanofibers compared to its free peptide
counterpart (164). Overall, these studies support the potential of an engineered pro-angiogenic
proteoglycan using conjugated QK in accelerating healing of ischemic dermal wounds.
3.2.2.2 Integrin-binding Peptide “LXW7”
While the VEGF-mimicking QK peptide presents a straightforward approach of direct
VEGF receptor activation, an integrin-binding peptide offers an alternative indirect mechanism
of activating VEGF pathways through cross-talk and synergy between integrins and VEGF
receptors. Additionally, as the proposed therapy is ECM-based, it follows that an integrinbinding peptide may further facilitate cellular transduction of this extracellular therapy. Integrins
are important mediators and transducers of interactions between cells and their surrounding
extracellular matrix, directly facilitating cellular attachment and migration and activating
signaling cascades that alter gene expression and stimulate proliferation (167). In addition to
acting as effectors of extracellular matrix cues, integrins have also been implicated in signal
transduction of soluble cues such as pro-angiogenic growth factors (168). For instance, Byzova
et al. reported that VEGF enhances adhesion and stimulates migration through the simultaneous
activation of multiple integrins, including αvβ3, αvβ5, α5β1, and α2β1, via VEGFR2 (168). In
particular, the activated αvβ3 integrin is the most abundant and influential in promoting
angiogenesis (169-171), as VEGF has been shown to increase adhesion and migration in an
αvβ3-dependent manner and activates αvβ3 more effectively than other angiogenic factors such
as bFGF, IL-1, IGF, and PDGF (168). Moreover, the αvβ3 integrin has been reported to have
many additional roles in angiogenesis, including localizing active MMP-2 on the vessel surface
to promote ECM remodeling during endothelial invasion (172) and preventing endothelial
apoptosis during active angiogenesis (168, 173). The current understanding is that VEGFR2
activation and integrin activation are heavily interrelated and synergistic in that activation of
either receptor class induces binding and activation of the other (174); VEGF activates VEGFR2,
physically associates with the β3 subunit to mediate VEGFR2 phosphorylation (170), signals
through PI3-kinase/Akt and c-Src, and thereby increases the affinity of αvβ3 integrin to the
extracellular matrix. Furthermore, anti-αvβ3 antibodies inhibit phosphorylation of VEGFR2
(170). Recent studies of the cross-talk between the VEGFR and αvβ3 integrin reveal an
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additional complexity whereby VEGF interactions with the extracellular matrix also modulate
the VEGFR/integrin associations, affecting VEGFR clustering and prolonging activation (156).
The use of conjugated LXW7 pro-angiogenic peptide (cyclized cGRGDdvc) capitalizes
on the aforementioned cross-talk between the integrin and VEGF signaling pathways while
simultaneously providing added benefits of promoting cell attachment and recruitment through
direct binding to integrins. This cyclic RGD peptide with unnatural D-amino acids was
discovered through one-bead-one-compound screening technology to bind αvβ3 integrin with
high affinity and specificity (150). When administered in free-peptide form, its integrin-binding
properties are antagonistic to αvβ3-overexpressing cells, providing neuroprotection from cerebral
edema after ischemic stroke by downregulating VEGF pathways (175, 176). In contrast, when
surface-bound, LXW7 has been found to activate the VEGF pathway indirectly through specific
binding αvβ3 integrin on both mature endothelial cells and endothelial progenitor cells (EPCs)
over other blood cell types such as platelets and monocytes, and improving endothelial
proliferation and directly facilitating endothelial attachment (149). This increased endothelial
attachment could improve EPC recruitment and/or support exogenous EPC delivery, which may
have profound effects in accelerating ischemic diabetic wound healing.
In addition to the promising potential of VEGF-based therapies for ischemic diabetic
wound healing, methods of increasing EPCs at the wound site have been implicated as a
therapeutic target because 1) ischemia has been found to significantly decrease the number of
EPCs delivered to excisional wounds (177) leading, at least in part, to delayed healing and 2)
EPC recruitment has been shown to be impaired in diabetic chronic wounds (43). During tissue
granulation, both local endothelial cells and bone marrow-derived endothelial progenitor cells
(EPCs) participate in neovascularization; endogenous EPCs mobilize into systemic circulation
through VEGF-induced endothelial nitric oxide synthase (eNOS) activation (39, 40) and are
recruited to the wound by SDF-1α, where they promote angiogenesis by expressing high levels
of VEGF and bFGF (39, 40). In diabetes, EPCs have both impaired mobilization (due to reduced
eNOS activity) and homing (due to reduced SDF-1α at the wound), resulting in less EPCs
present in circulation (41-43) and at the wound site (43), respectively. Support for the
therapeutic benefit of increasing EPCs in diabetic ischemic wounds has been exemplified by
Asai et al.’s study, where exogenously administered EPCs accelerated wound closure in diabetic
mice by incorporating into the vasculature and increasing angiogenesis and granulation (39).
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Taken together, the conjugation of LXW7 to our decorin mimic has the potential for angiogenic
capacity with expanded therapeutic benefit.

3.3
3.3.1

Materials and Methods
Materials
All peptide-hydrazides were synthesized in our lab with standard Fmoc amino acids,

DIC, OxymaPure, and piperidine purchased from Aapptec. QK peptide with N-terminal
acylation and C-terminal amidation was custom synthesized by GenScript, >90% purity. All
organic solvents and premium grade EDC were purchased from Fisher.
3.3.2

Synthesis of Pro-angiogenic and Collagen-binding Peptide-hydrazides
Modified pro-angiogenic peptide-hydrazides of QK and LXW7 and collagen-binding

peptide-hydrazide SILY (sequences in Table 3-1 and chemical structures in Figure 3-3) were
synthesized based on a previously published protocol for generating hydrazide-loaded 2chlorotrityl chloride resin (178) and standard Fmoc solid phase peptide synthesis. 2-chlorotrityl
chloride resin (1.51 mmol/g, Anaspec) was rinsed sequentially 3 times with DMF, DCM, and
DMF, and then swollen in 50% DCM/DMF for 1 hour. The resin was then reacted with 10%
hydrazine hydrate (85%, Sigma) in synthesis grade DMF (Fisher) and 0.057M DIPEA (Fisher)
for 2 hours at room temperature while bubbling under nitrogen. The solution was drained and
the resin was reacted again with fresh solution for 1 more hour, after which the resin was washed
3 times with DMF and reacted with 10% methanol in DMF to cap any remaining unreacted
chloride groups. The hydrazide-resin was washed again 3 times with DMF and then reacted
directly with the first amino acid (4 equivalents) with HOBt/HBTU (4 equivalents) and DIPEA
(10 equivalents) bubbling under nitrogen overnight at room temperature. After coupling, resin
was washed thoroughly with 2x DMF, 2x DCM, IPA, and then 2x DMF. Subsequent amino
acids were coupled for 20 minutes to 1 hour each at 50C on a Liberty Blue automated microwave
peptide synthesizer (CEM) using 5 equivalents each of Fmoc-amino acids (Aapptec), DIC, and
OxymaPure with 0.1M DIPEA and deprotected with 20% piperidine in synthesis grade DMF for
3 minutes at 60C. For N-terminal biotinylation, 5 equivalents of D-biotin (Anaspec) was
coupled with 4 equivalents HBTU/HOBt and 10 equivalents DIPEA overnight at room
temperature. Peptides were cleaved for 3 hours with 88% TFA, 5% phenol, 5% H2O, and 2%
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TIPS and precipitated with cold diethyl ether. Crude peptides were redissolved in 5%
acetonitrile and purified to >90% purity through a C18 prep column (Spirit) against an
acetonitrile (HPLC grade) gradient on an AKTApure 25 FPLC (GE Healthcare) and confirmed
by MALDI-TOF mass spectrometry (Bruker). Before purification, cyclization of LXW7 was
performed by oxidizing cysteine residues to form intramolecular disulfide bridges with ClearOx
resin (Peptides International) according to the manufacturer’s protocol.

Table 3-1. Peptide Sequences and Conjugation Efficiency
Sequences in 1 letter amino acid format from N to C terminus, where upper case letters indicate L-amino acids and
lower case letters indicate unnatural D-amino acids, Ac indicates acetylation of the N terminus, and aeea is a short
(2-(2-aminoethoxy)ethoxy)acetic acid spacer (ChemPep, Inc.) resembling PEG2. All peptides were synthesized in
our laboratory, with the exception of QK, which was custom-ordered from Genscript. Conjugation efficiency is
defined as the ratio of conjugated peptide to total peptide in the reaction feed, where the total peptide was the
limiting reagent. The conjugation efficiency is thereby a measure of reaction completion. For example, a
conjugation efficiency of 100% indicates that all peptide added in the reaction feed was successfully covalently
conjugated to the dermatan sulfate.
Peptide
Name

Sequence

Chemical
Formula

QK
V
Peg2V
LXW7
SILY

Ac- KLT WQE LYQ LKY KGI-amide
KLT WQE LYQ LKY KGI GSG-hydrazide
KLT WQE LYQ LKY KGI –(aeea)2-GSG-hydrazide
cG RGD dvc -(aeea)2-WG-hydrazide
RRA NAA LKA GEL YKS ILY GSG-hydrazide

C94H146N22O23
C99H156N26O26
C111H178N28O32
C54H84N18O20S2
C99H166N32O28

Molecular
Weight
(g/mol)
1952.2
2126.5
2416.8
1369.5
2252.6

Peptide
Conjugation
Efficiency
N/A
75%
66-78%
35-40%
95-100%

peptides
QK: Ac-KLT W QE LYQ LKY KGl-amide
V:

KLT W QE LYQ LKY KGI GSG-hydrazide

Peg2V:

KLT W QE LYQ LKY KGI -aeea2-GSG-hydrazide

V: 'QK' -GSG-hydrazide

Molecu lar Weight: 2126 .49

avJ33 lntegrin-binding peptide
(cyclic RGD)
LXW7:
cGRGDdvc
Modified LXW7: cGRGDdvc-aeea2-W G-hydrazide
'LXW7'-aeea2-WG-hydrazide
Molecular Weight: 1369.49

Peg2V: 'QK' -aeea2-GSG-hydrazide

Molecular Weight: 2416.81

Red = aromatic residues detectable at 280 nm absorbance

Figure 3-3. Chemical Structures of Synthetic Peptide-hydrazides
‘GSG’ tripeptide spacer sequences and/or aeea short PEG linkers were added to the C-termini of active sequences immediately preceding the C-terminal
hydrazide. Note that αvβ3 integrin-binding peptide ‘LXW7’ is an RGD peptide cyclized by a disulfide linkage between flanking D-cysteines. Sequences are in
single letter amino acid notation with upper case letters indicating natural L-amino acids and lower case letters indicating unnatural D-amino acids. Aromatic
residues that could be detected by 280 nm absorbance and specific autofluorescence wavelengths (W: excitation 295 nm, emission 350 nm; Y: excitation 280 nm,
emission 305 nm) are highlighted in red text.
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3-1 continued

peptide
SILY:
RRA NAA LKA GEL YKS ILY
Modified SILY: RRA NAA LKA GEL YKS ILY GSG-hydrazide

Molecular Weight: 2252.6
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3.3.3

Peptide-hydrazide Conjugation to Dermatan Sulfate

3.3.3.1 EDC-activated Reaction with Peptide-hydrazide
The peptide-hydrazide conjugation reaction scheme is depicted in Figure 3-4. Carboxylic
acids on dermatan sulfate (Celsus Laboratories, average MW ~46275) were activated with
premium grade EDC (thermofisher) for 5 minutes in 0.1M MES buffer with 8M urea titrated to
pH 4.5. Peptide-hydrazides were pre-dissolved in reaction buffer before addition to the activated
DS solution with a final DS concentration of 10 mg/mL. In all reactions, the peptide-hydrazide
was the limiting reagent. After 2 to 48 hours, the reaction was stopped by titrating to pH 8 with
0.5M NaOH for 30 minutes. The product was then purified by size-exclusion through 2
desalting columns (10 mL Bio-gel P6 desalting cartridges, Bio-Rad) in series on an AKTA
purifier FPLC (GE Healthcare) and then lyophilized. For constructs with two different peptides,
peptides were reacted sequentially with more EDC added upon conjugation of the second
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peptide, after taking a small sample of the reaction to quantify addition of the first peptide.
Biotinylated molecules for detection of surface binding were similarly synthesized by
sequentially conjugating 1 equivalent of biotinylated peptide followed by the desired equivalents
of non-biotinylated peptide, taking into account conjugation efficiency. For example, a
biotinylated DS-SILY4 was synthesized by reacting 1 equivalent of biotinylated-SILY-hydrazide
followed by 4 equivalents of SILY-hydrazide; a biotinylated DS-peg2V2 was synthesized by
reacting 1.33 equivalents of biotinylated-peg2V-hydrazide followed by 4 equivalents of peg2Vhydrazide. DS control molecules were also synthesized by reacting DS under the same
experimental conditions with and without EDC, labeled “EDC-reacted DS” and “processed DS,
no EDC” respectively, for 24 hours but without peptide. These products were also purified by
size-exclusion to remove buffer salts and any unreacted EDC.
3.3.3.2 DMTMM-activated Reaction with Peptide-hydrazides
Synthetic chemistry replacing EDC with and (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4methyl-morpholinium chloride) (DMTMM) was performed similarly to the EDC method
described above with slight modifications. DS was reacted with 4 equivalents of SILY overnight
with 100 equivalents of DMTMM (Alfa Aesar) in 0.1 MES buffer with 8M urea (titrated to pH
4.5). A small sample of the solution was removed and purified by size-exclusion
chromatography and lyophilized to determine completion of the DS-SILY reaction. Immediately
prior to addition of LXW7, 100 equivalents more DMTMM was added to the remaining solution
and left to react for either 4 hours or 28 hours before purification by size-exclusion
chromatography and lyophilization. All experiments were run at room temperature except when
testing the effects of heating the reaction to 37°C in an incubated plate shaker (VWR).
3.3.4

Quantification of Conjugated Peptides
All peptides were detected by concentration dependent 280 nm absorbance of aromatic

amino acids on a NanoDrop One UV-Vis spectrophotometer (ThermoFisher). For increased
specificity on molecules with multiple peptides, peptide quantification was confirmed by
detection of intrinsic tryptophan (ex295 nm, em350 nm) and tyrosine (ex280 nm, em305 nm)
autofluorescence on a SpectraMax M5 plate reader (Molecular Devices) in UV transparent 96-
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well plates (Corning). All samples were prepared at 2 mg/mL in ultrapure water and analyzed by
taking the average of 5 repeated readings.
3.3.5

Nomenclature of QK and LXW7-derived peptide-hydrazides and pro-angiogenic
decorin mimics
QK-derived peptide-hydrazides (sequences in Table 3-1 and chemical structures in Figure

3-3) were named V and peg2V to describe the QK sequence with added GSG-tripeptide and
GSG-aeea2 (PEG4 spacer) on the C-termini, respectively. LXW7-derived peptide hydrazide
with an aeea2-WG spacer at the C-terminus is referred to as LXW7 for simplicity. Engineered
molecules were given the following nomenclature to indicate the type and number of conjugated
peptides per DS: DS-(peptide)substitution#. For example, a decorin mimic composed of a dermatan
sulfate backbone and 4 SILY substitutions per DS is referred to as DS-SILY4; a mimic with 3 V
peptides per DS is referred to as DSV3 and a mimic with 3 peg2V peptides per DS is referred to
as DS-(peg2V)3. Pro-angiogenic decorin mimics are indicated as (peg2V)substitution#-DS-SILY4 or
substitution#LXW7-DS-SILY4 to emphasize the differing degrees of LXW7 substitution on
LXW7-DS-SILY4 variants. Degrees of substitution are rounded to the nearest 0.5 for simplicity.
3.3.6

Circular Dichroism (Secondary Structure Characterization of Peptides)
Circular dichroism spectra of peptides at 21.8 µM and constructs with equivalent total

peptide concentrations were collected at room temperature in 0.01M potassium phosphate buffer
(pH 7.1) from 185 nm to 260 nm with 4 accumulations at 50 nm/min scan speed and 4 sec DIT
in 1 mm quartz cuvettes (Starna) on a Jasco J-1500 CD Spectrophotometer. CD data is
converted and presented as molar ellipticity, [θ], in deg×cm2/dmol,
θ

[θ] = 100 ∗ -C∗l

,

where θ is the degrees ellipticity, C is the molar concentration, and l is the pathlength in cm. CD
spectra of conjugated peptides were calculated by collecting the spectra of the DS-peptide
constructs with concentration adjusted to obtain 21.8 µM conjugated peptide and then
subtracting out the signal for an equivalent concentration of EDC-reacted DS.
3.3.7

2-Dimensional Nuclear Magnetic Resonance
High resolution 1H, 13C, and HSQC NMR spectra of 45 mg/mL dermatan sulfate in D2O

were acquired for 6 hours on a Bruker instrument.
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3.3.8

Nanodrop Absorbance Spectra
2 mg/mL samples were evaluated by absorbance spectral sweeps from 220 nm to 350 nm

acquired on a NanoDrop One Spectrophotometer (ThermoScientific).
3.3.9

Characterization of Molecule Binding to Collagen- and Fibrinogen-coated Surfaces
High-binding 96-well plates (Corning) were coated with 50 µg/mL rat tail collagen I

(Corning) at 4°C overnight or 2% reduced growth factor Matrigel (Corning # 354230) in basal
EBM media for 30 minutes at 37°C and rinsed 3x with PBS before blocking non-specific binding
with 1% Bovine Serum Albumin (BSA) for 1 hour at room temperature. For fibrinogen surfaces,
a fibrinogen coating solution of ~2.75 mg/mL fibrinogen (Sigma) and 5.5 µg/mL aprotinin
(Sigma) was incubated at 4°C overnight in high-binding plates. Biotinylated samples dissolved
in 1% BSA were allowed to bind to the surface for 30 minutes at 37°C on a plate shaker. After 3
washes with PBS, wells were incubated with 1:200 streptavidin-HRP in 1% BSA, rinsed 3x with
PBS, developed with a 1:1 A to B color solution for 20 minutes, stopped with the addition 2N
H2SO4, and read on a Spectramax M5 platereader for absorbance at 450 nm with 540 nm
correction.
3.3.10 Characterization of Binding and Activation of VEGF receptor 2 (VEGFR2)
3.3.10.1 VEGF-mimicking Peptide Binding to VEGFR2
Binding affinity was determined using bio-layer interferometry on an Octet® RED384
system (Pall ForteBio). Amine-Reactive Second-Generation (AR2G) biosensors were
equilibrated in ultrapure water for 5 minutes prior to starting the protocol. Briefly for biosensor
preparation involving VEGFR2 immobilization to the sensor, AR2G biosensors were
equilibrated in ultrapure water for 1 minute, activated with 20mM EDC and 10mM sNHS for 5
minutes, loaded with a 25 µg/mL solution of VEGFR2 in pH 5 sodium acetate buffer for 20
minutes, and then remaining unreacted carboxylic acids were quenched with ethanolamine for
7.5 minutes (Figure 3-17A). Optimal timing of each step was determined experimentally to
ensure stable equilibrium before proceeding to the next step. The prepared sensors were then
immersed in equilibrating 1% milk blocking solutions for 3 minutes before exposure to VEGF or
V solutions in 1% milk for 15 minutes and then in 1% milk for 15 minutes to assess VEGF and
V association and dissociation, respectively, from the VEGFR2-coated surfaces. Subsequent
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calculation of the equilibrium dissociation constant, KD, was calculated using ForteBio analysis
of association and dissociation curves generated from multiple analyte concentrations.
Concentration gradients used for VEGF were 2 fold serial dilutions from 0.30 nM to 9.5 nM,
while those used for V were 94 µM to 3 mM diluted in 1% milk blocking solution.
3.3.10.2 Endothelial VEGFR2 Activation
3.3.10.2.1 Cell Culture
Human Dermal Microvascular Endothelial Cells (HMVEC, Lonza CC-2543) and Human
Umbilical Vein Endothelial Cells (HUVEC, Lonza CC-2935) were expanded according to the
manufacturers’ protocol in EGM2-MV media and EGM-Plus media, respectively, and passaged
at 70-90% confluence. Cells were cryopreserved in 80% media, 10% sterile DMSO, and 10%
FBS. For experiments, HMVECs were used between passages 6 and 8, and HUVECs were used
between passages 3 and 6 and maintained at 37C and 5% CO2.
3.3.10.2.2 Multiplexed MesoScale Discovery (MSD) assay
HUVECs or HMVECs were seeded at 20000 cells per well in complete EGM-Plus growth
media or complete EGM2-MV, respectively. 24 hours after plating, the media was replaced with
serum-free, growth factor-free basal media (EBM) to serum-starve and synchronize the cells for
24 hours. The next day, the media was replaced with treatments, dissolved in EBM, for 5
minutes and treatment removed and cells immediately lysed with 50 µL per well of complete
lysis buffer (MSD) for 30 minutes on ice. Lysates were frozen at -80C until further analysis for
phosphorylated VEGF receptor 2 and total VEGF receptor 2 using a custom ELISA-type
Multiplexed MesoScale Discovery (MSD) assay performed according to the manufacturer’s
protocol.
3.3.11 Statistical Analysis
All quantitative data is presented as mean ± standard deviation, and statistical significance
was evaluated by ordinary one-way ANOVA using post-hoc Dunnett’s or Tukey’s tests for
multiple comparisons with values p < 0.05 denoted as significant.
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3.4

3.4.1

Results and Discussion
Pro-angiogenic Decorin Mimic Design and Development

3.4.1.1 Design of Quantifiable Peptide-hydrazide Sequences with Preserved Postconjugation Bioactivity
Active peptide sequences from literature were modified with short amino acid and/or
short PEG spacer sequences to ensure that the peptides were freely accessible for cellular
interactions after conjugation to dermatan sulfate. All peptides were synthesized as C-terminal
hydrazides to allow preferential C-terminal EDC-conjugation over internal primary amines at
low pH. Although unmodified QK and SILY peptides both contain multiple aromatic amino
acids facilitating conjugated peptide quantification using 280 nm absorbance and intrinsic
autofluorescence, the original LXW7 peptide sequence needed to be further modified by addition
of a C-terminal tryptophan for ease of downstream non-destructive quantification. As expected
based on greater 280 nm absorbance for tryptophan compared to tyrosine, we found that the 280
nm absorbance method was more sensitive for quantification of QK-derived peptides and LXW7
than SILY (Figure 3-5). Non-destructive quantification of 2 different sequentially conjugated
peptides by analyzing 280 nm absorbance of samples immediately before addition of the second
peptide provided adequate substitution estimates under the assumption that the conjugation
reaction of the first peptide was complete. We achieved more specific quantification of final
peptide substitution on proteoglycan mimics containing both LXW7 and SILY measuring
intrinsic autofluorescence of tryptophan (ex295 nm, em350 nm) and tyrosine (ex280 nm, em305
nm). For this particular peptide combination, the autofluorescence parameters allowed for
specific detection of each peptide without significant signal interference from the other peptide
(Figure 3-6). Quantification of mimics with both QK-derived peptides and SILY was also
possible by the UV autofluorescence method, although the tyrosine signal included contributions
from both peptides.
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Tryptophan and Tyrosine as a Linear Function of Peptide Concentration.
These standard curves were used as a high throughput, non-destructive method to quantify peptide conjugation.
UVautofluorescence of Tryptophan > UVautofluorescence of Tyrosine.

3.4.1.2 Optimization of Peptide-specific EDC-hydrazide Conjugation Chemistry
In the synthesis process, we discovered that peptide conjugation efficiency (defined as
peptide equivalents successfully attached out of total reacted equivalents) to the dermatan sulfate
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backbone was peptide dependent. Coupling of SILY was nearly 100% efficient after 2 hours of
reaction, while coupling of QK-derived peptides was only ~70% efficient after a 4 hour reaction
and coupling of LXW7 suffered the lowest efficiency at ~35-40% even after 48 hours of reaction
and additional EDC (Table 3-1). In addition to peptide-specific conjugation efficiencies, we also
found that comparable conjugation of SILY equivalents, as assessed by similar 280 nm
absorbance, could be achieved with EDC activation of as few as 20% of the available carboxylic
acids on DS (assuming approximately 100 carboxylic acids per dermatan sulfate) (Figure 3-7),
whereas similar reduction of EDC significantly negatively impacted LXW7 conjugation. Given
the vast differences in peptide conjugation efficiencies, it is likely that structural and steric
effects affect the chemistry in a sequence-specific manner. We attempted to improve LXW7
coupling by using linear LXW7 in hopes of reducing steric hindrance during conjugation and
cyclizing the peptide after conjugation; however, Ellman’s assay revealed significantly fewer
free thiols than expected after conjugation and it was determined that the thiols in the linear
peptide were consumed through irreversible reaction with EDC (Figure 3-8), an observation that
is supported in literature (179). By adjusting several experimental parameters, including
lengthening reaction time, better controlling pH, increasing peptide equivalents, and adding more
EDC over the course of the reaction, we achieved a maximum of 5.5 cyclized LXW7 peptides
per DS. In dual peptide conjugation, we also discovered that the order of peptide addition was
crucial to achieving desired peptide substitution. SILY conjugation efficiency drastically
decreased to 20-50% when it was added as the second peptide (depending on the identity and
quantity of the first peptide), while other peptides appeared to maintain relatively constant
conjugation efficiency regardless of addition order; therefore, SILY peptides were added first in
a dual peptide conjugation sequence.
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3.4.1.3 Peptide-hydrazide Conjugation using DMTMM: Pilot Studies
Given the low conjugation efficiency of LXW7 using EDC, pilot studies replacing EDC
with the DMTMM activator were investigated in the synthesis of LXW7-DS-SILY constructs,
based on improved conjugation by DMTMM over EDC/NHS observed by D’Este et al. in
hyaluronan substitution studies of reactions over 5 days (180). LXW7-DS-SILY constructs were
synthesized by first conjugating SILY to form DS-SILY4, and then sequentially adding desired
equivalents of LXW7 to the reaction feed. First, we observed that the DMTMM reaction
proceeded more slowly than EDC, as some unreacted SILY remained in a 2 hour DMTMM
reaction, which was not present for a 2 hour EDC reaction. The DMTMM reaction needed to be
extended overnight for complete conjugation of 4 equivalents of SILY. Furthermore, in this
initial synthesis of DS-SILY4 after an 18 hour overnight reaction with DMTMM, we observed a
280 nm absorbance of ~0.37, representing a super-theoretical calculated conjugation efficiency
of SILY (calculating >4 equivalents conjugated SILY, whereas only 4 equivalents of SILY was
added to the reaction). In comparison, 280 nm absorbance was ~0.27 for the corresponding DSSILY4 sample synthesized with EDC in a 2 hour reaction, representing 100% conjugation
efficiency of 4 SILY equivalents. The super-theoretical 280 nm absorbance observed in the
DMTMM reaction might be attributed to some co-purified or conjugated DMTMM that did not
separate as effectively by size-exclusion chromatography and may cause additional sample
absorbance at 280 nm. After sequential LXW7 conjugation, net absorbance values were used to
calculate additional absorbance attributed to conjugated LXW7, and the calculated degree of
substitution for the tested reaction conditions are presented in Table 3-2. Note that there was a
total of 200 equivalents of EDC or DMTMM activator added to the batch reaction, where the
first 100 equivalents were added for SILY conjugation and the next 100 equivalents were added
immediately prior to LXW7 conjugation.
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Table 3-2. Degree of LXW7 substitution of LXW7-conjugated DS-SILY constructs synthesized by EDC versus
DMTMM activation of carboxylic acids on DS.

200 eq. total EDC
Reaction time
18 hours
48 hours
200 eq. total DMTMM
Reaction time
4 hours
28 hours
48 hours

5 eq LXW7
1.9
--

LXW7 equivalents added
10 eq LXW7
3.3
4.0

20 eq LXW7
4.6
4.7

LXW7 equivalents added
5 eq LXW7
10 eq LXW7
1.3
2.5
3.2
8.4
-8.7

DMTMM activation significantly improved LXW7 conjugation efficiency over EDC for
equivalent LXW7 reactant concentrations, reaching ~87% within 48 hours with 10 equivalents of
LXW7 added. Although longer reaction time significantly improved the LXW7 conjugation
with DMTMM, there was still unreacted product even after 48 hours. Given that the LXW7
conjugation appeared to conjugate slower than SILY or QK conjugation (both peptides reached
>60% completion within 4 hours) based on the EDC reaction and that DMTMM reactions
progressed slower than EDC reactions, we then tested whether reaction heating could accelerate
conjugation. The results for reactions at 37°C are presented in Table 3-3.
Table 3-3. Degree of LXW7 substitution of LXW7-conjugated DS-SILY constructs synthesized by room
temperature versus heated DMTMM reaction.

200 eq. total DMTMM
Reaction time
24 hours
48 hours

10 equivalents of LXW7 added
Room Temp
37°C
6.8
6.1
8.7
6.9

Heating the DMTMM-activated reaction unexpectedly decreased the efficiency of conjugation in
our studies, contrary to findings reported by Loebel et al. where heating to 37°C improved
conjugation of tyramine to hyaluronan at all reaction times until 120 hours (181). Interestingly,
Loebel et al. also observed that at 37°C, maximal conjugation occurred after ~10 hours but then
decreased conjugation over increasing reaction time, suggesting that the conjugation was
reversible and/or the tyramine degraded or detached from the hyaluronan after prolonged
heating. In contrast, conjugation continuously improved over 120 hours with DMTMM at room
temperature. If the DMTMM conjugation of peptide-hydrazides progresses similarly to that
described in Loebel et al., it is possible then that the tested heated reaction times are too long and
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maximum conjugation could be reached prior to 24 hours. However, since we observed a slight
increase in conjugation with prolonged heating at 48 hours, additional studies investigating both
shorter and longer time points for the heated reaction may be necessary to understand the
kinetics of the heated reaction. Based on the preliminary results, we do not suggest heating the
DMTMM reaction for our synthetic scheme unless these additional heated studies are performed,
as we achieved the greatest conjugation efficiency at prolonged room temperature reactions.
3.4.2

Characterization of Free and Conjugated Peptides

3.4.2.1 Modified VEGF-mimicking Peptides Maintain Alpha-helical Secondary Structure
Before and After Conjugation
From its conception, QK peptide’s α-helical secondary structure was determined to be
crucial to its pro-angiogenic bioactivity (159). Thus it was important to first determine any
peptide conformational changes upon spacer and hydrazide C-terminal modifications, as single
amino acid modifications can have significant effects on secondary structure and the addition of
a ‘GSG’ tripeptide spacer was predicted by computational modeling to cause C-terminal
uncoiling (Figure 3-9). Upon conjugation to dermatan sulfate, the VEGF-mimicking peptides
could also change in structure, as some proteins have been reported undergo conformational
and/or structural changes after binding to glycosaminoglycans (GAGs). For example, Wijelath et
al. reported evidence of heparin modulation of VEGF-A165 (but not VEGF-121) secondary
structure, increasing α-helical content (182). Peptide secondary structure is commonly detected
by circular dichroism (CD) analysis through identification of characteristic spectral signatures,
with an α-helical signature represented by negative peaks at 208 nm and 222 nm and a positive
peak at 193 nm. We therefore used CD to investigate 1) whether the modified VEGF-mimicking
peptides maintained alpha helical structure before conjugation and 2) whether the close
association of peptides with DS after conjugation would alter their structure. As seen in Figure
3-10A, CD spectra of modified QK peptides (V and peg2V) very closely matched the original αhelical QK signature, despite the addition of GSG tripeptide and GSG-peg2 C-terminal spacers
for V and peg2V respectively and C-terminal hydrazide modification. Importantly, as seen in
Figure 3-10E, V and peg2V also maintained the α-helical signature after conjugation to dermatan
sulfate, since the differences between the conjugated and free peptide CD spectra were minimal.
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This is an essential finding as it demonstrates that the close proximity of the highly negatively
charged dermatan sulfate molecule does not distort peptide secondary structure.

KLTWOELYOLKYKGI

KLTWOELYOLKYKGI-GSG

KLTWOELYOLKYKGI-GC

Figure 3-9. Theoretical Secondary Structure of VEGF-mimicking Peptide Sequences Modeled by PepFold
Software (183, 184).
Top row is a cartoon representation, emphasizing overall backbone secondary structure of the peptide indicated in
the upper right corner with the peptide sequence specified above each column. Bottom row represents the
corresponding wire model structure highlighting the orientation of side chain projections. “VEGF15” is the native
peptide sequence present spanning the VEGF receptor 2 binding region, which was found experimentally by CD to
be uncoiled outside the context of the full VEGF protein by D’Andrea et al (159).

For a comprehensive analysis, we also investigated CD of LXW7 and SILY peptides
before and after conjugation to dermatan sulfate. In comparison to the α-helical structure of
VEGF-mimicking peptides, LXW7 had a slight negative signal from 185 to 205 nm and almost
no CD signal in other wavelengths examined, while SILY revealed a signature resembling a
random coil of a denatured triple-helix with a minimum at 198 nm and low ellipticity above 210
nm (185). Like free LXW7, conjugated LXW7 also had almost no CD signal, although the
minimal signal was slightly positive in the 185 to 205 nm range (Figure 3-10F). For SILY
peptide, conjugation resulted in a significantly more negative and slightly right shifted spectrum
but still lacking a positive signal in the 210 to 230 nm range, perhaps indicative of a slightly
more organized collagen-like triple helix (Figure 3-10F). A finding of a collagen-like triple helix
signature for SILY peptide is not surprising and may help SILY bind to fibrillar collagen.
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Figure 3-10. Circular Dichroism (CD) Spectra of Peptides Before and After Conjugation to Dermatan Sulfate.
CD spectra of free peptides (A) and DS-conjugated peptides (E & F). Subfigure B shows DS structural changes
caused by reaction with EDC alone, which served as a background signal that was subtracted from total CD signal
observed from peptide-conjugated DS constructs (C & D). Subfigure C highlights the differences in CD signal from
DSV3 compared to DS(Peg2V)3, indicating changes attributed to the addition of a short peg linker present in peg2V.
It also highlights that the deepened negative peak around 198 nm and positive peak 235 nm are more pronounced in
DSV1, which is measured at a higher overall concentration to keep peptide concentration constant, and exhibits the
same major features seen in the EDC-reacted DS curve in subfigure B. Subfigure D highlights overall CD
differences between the DS(Peg2V)3, DS(LXW7)4, and DS-SILY4 constructs.
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3.4.3

EDC Activation Produces Irreversible Structural Changes in Dermatan Sulfate
In gathering the CD spectrum of V peptide conjugated to DS (denoted DSV), we

discovered that lower substitution DSV1 had a greater negative peak around 200 nm than DSV3
(Figure 3-10C). Since the DSV1 concentration assessed was 3 times greater than DSV3 in order
to match samples for total peptide concentration, the larger negative peak was attributed to a
higher overall concentration of DS. Upon background subtraction of the unmodified DS spectra,
the resultant curves generally followed the expected α-helical features but displayed unexpected
positive features in the 225 to 245 nm range (data not shown). This led us to explore changes in
the DS spectra coming from the EDC reaction. In this investigation, we observed an unexpected
change in the CD spectra of EDC-reacted DS (Figure 3-10B), indicating a GAG
structural/conformational change induced by the EDC reaction. The CD spectrum had
pronounced deepening of the negative peak around 200 nm and a new positive peak at 235 nm,
most closely resembling the CD spectra of intact collagen triple helices (185) although the
positive peak is slightly more right-shifted. Since the products were purified by size-exclusion
prior to CD analysis, these changes could be attributed to covalent addition of EDC or copurified EDC due to strong association. We then used 1H and 13C 2D NMR analysis, which
revealed multiple new protons at 1, 1.1, 2.8, 3, 3.1, and 3.2 ppm (Figure 3-11A) and new carbons
at 14, 15, 25, 35, 36, and 160 ppm on DS after the EDC reaction (Figure 3-11B). Additionally,
absorbance spectral sweeps seen in Figure 3-12 demonstrated increased absorbance at 220 nm
proportional to the amount of reacted EDC, likely due to new imide bonds (resembling amide
bonds). CD, NMR, and absorbance data together indicate that EDC reacted covalently and
irreversibly through O-acylisourea rearrangement to stable N-acylurea after carboxylic acid
activation (Figure 3-4). Furthermore, the progressive increase in 220 nm absorbance with 20
equivalents versus 100 equivalents of EDC in Figures 3-7 and 3-12 suggested that the DS-SILY4
synthesized with 20 versus 100 equivalents of EDC differed in the amount of N-acylurea
attached to the DS backbone.
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Figure 3-11. 1H Proton NMR (A) and 13C Carbon NMR (B) Spectra of Unmodified DS, EDC-reacted DS, and
DMTMM-reacted DS.
Multiple new protons and carbons are found on EDC-reacted DS compared to unmodified DS.
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3.4.4

Potential Biological Implications of N-acylurea
Irreversible N-acylurea formation with EDC has been well documented in literature (186,

187), and is likely more abundant in the given reaction due to the lack of NHS, even though the
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molar ratio of EDC to carboxylic acid groups was approximately 1:1. Due to modification of the
carboxylic acid, the N-acylurea EDC adduct would reduce the overall negative charge on DS at
neutral pH. The change in charge is the most likely cause of the observed conformational
change and potentially affects DS’ electrostatic interactions with other biological molecules.
These types of EDC-altered molecule interactions have previously been reported on proteins by
Huckett et al. (188), whereby electrostatic changes caused by N-acylurea altered protein binding
to DNA. Oliveira et al. also reported similar changes to GAGs, whereby the heparin binding to
cationic dyes, heparin susceptibility to heparinases, electrophoretic behavior, and anticoagulant
properties were impaired by EDC reaction (189). GAG-growth factor interactions are known to
be responsible for modifying growth factor biological activity, and thus these irreversible
changes to GAG charge and structure may significantly affect DS’ therapeutic activity.
In our preliminary investigation of the biological significance of the EDC-induced
changes, we compared the proliferative effects of DS-SILY4 synthesized with 20 versus 100
EDC equivalents on HMVECs. Our results suggested that a higher amount of N-acylurea did not
negatively impact and may even stimulate proliferation both in soluble (Figure 3-13A) and
collagen-bound forms (Figure 3-13B).

B)
Soluble Treatments
- 0.5
E

lii
(.)

...

~ 0.3

u::
...

::!..
C:

n,

.c

0

0.2

rJ>

.c
ni

rn

0.1

1-

:E 0.0

4

rJ>

~ 0.4

C:

Surface-bound Treatments

Q)
(.)

Q)

g3

E
2
n,

<(

~ 1
!::!

ro

E
o
0

z

Figure 3-13. Effects of increasing EDC on HMVEC Proliferation after 72 hour exposure to soluble treatments
and 144 hour exposure to surface-bound treatments.
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3.4.4.1 N-acylurea Addition to DS Impairs its Ability to Potentiate VEGF
To further explore the biological ramifications of N-acylurea, we studied changes in the
VEGF receptor activation and total VEGF receptor 2 levels in the presence and absence of
VEGF. Preliminary data showed that, in the absence of VEGF, unmodified DS and EDC-reacted
DS produced statistically identical responses, as measured by phosphorylated VEGFR2 and total
VEGFR2. Without VEGF, 5 minute stimulation with EDC-reacted DS decreased the total
VEGFR2 to the same degree as unmodified DS, and neither unmodified DS nor EDC-reacted DS
had any significant effect on phosphorylated VEGFR2 (Figure 3-14 A & B). However, in the
presence of VEGF, differences in activity were apparent. 5 minute VEGF stimulation resulted in
a significant increase in VEGFR2 phosphorylation (Figure 3-14D), while total VEGFR2 levels
decreased (Figure 3-14E), which can be accounted for by endocytosis and subsequent
degradation of activated VEGF receptors during recycling/desensitization. Unmodified DS
increased the VEGF-induced phosphoVEGFR2 (Figure 3-14D) and simultaneously prevented
receptor downregulation thereby prolonging the VEGF response (Figure 3-14E), a significant
finding has not yet been reported in literature. In contrast, the EDC-reacted DS was unable to
elicit increased phophoVEGFR2 or prevent VEGFR2 downregulation, showing no significant
effects compared to the VEGF control (Figure 3-14E). These findings dependent on the
presence of VEGF suggested that the N-acylurea addition did not significantly change intrinsic
DS interactions with the VEGF receptor, but caused altered DS interactions with VEGF that
perhaps prevent it from potentiating and/or prolonging VEGF responses. It is possible that the
altered charge and conformation of N-acylurea addition does not allow effective VEGF binding,
or alternatively the DS may be binding up VEGF and other growth factors in a manner that does
not synergize their activities.
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3.4.4.2 SILY Addition to DS does not Affect Total VEGFR2 Levels, but Decreases
VEGFR2 Phosphorylation and N-acylurea Exacerbates this Effect
Interestingly, the addition of SILY changed the dynamics of the DS with VEGF receptors
in both the absence and presence of VEGF. In the absence of VEGF, while DS-SILY4 had no
effect on total VEGFR2 compared with DS (Figure 3-14B), DS-SILY4 with 20 EDC equivalents
decreased phosphoVEGFR2 below the DS and untreated controls, and this effect was amplified
in DS-SILY4 with 100 EDC equivalents (Figure 3-14A). SILY addition thereby appeared to
decrease constitutive VEGFR2 phosphorylation, and greater amounts of N-acylurea seemed to
exacerbate this effect. In the presence of VEGF, DS-SILY4 with 20 EDC equivalents had a
similar effect as unmodified DS on total VEGFR2 (Figure 3-14E), allowing a prolonged
response by preventing VEGFR2 degradation. In contrast, DS-SILY4 with 100 EDC equivalents
resulted in responses similar to EDC-reacted DS. Therefore the effects seen in the presence of
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VEGF is governed by the amount of N-acylurea. It follows that SILY addition itself did not
affect DS’ ability to prevent total VEGFR2 degradation in the presence of VEGF, but rather the
total VEGFR2 level caused by DS-SILY4 made with 100 EDC equivalents is governed by its
increased N-acylurea. Although SILY addition appeared to quench DS’ ability to potentiate
VEGF-induced receptor phosphorylation (Figure 3-14D), this can largely be attributed to the fact
that SILY itself decreases receptor phosphorylation. The even greater decrease in
phosphoVEGFR2 seen with DS-SILY4 made with 100 EDC equivalents is thus the result of a
combination of greater N-acylurea substitution prevented phosphoVEGFR2 synergy, and the
addition of SILY further negatively affected receptor phosphorylation.
The negative effect of SILY on VEGFR2 phosphorylation might be explained at least in
part by the fact that the SILY carries a positive net charge of 3+ per peptide, such that its
conjugation to DS not only eliminates a carboxylic acid, but also adds positive charge, serving to
change the overall charge of DS. Based on the VEGFR2 activation studies alone, DS-SILY4
should not stimulate endothelial proliferation, contrary to our observations in Figure 3-13 and
previously reported proliferative effects for DS-SILY20 using oxidation-type synthetic chemistry
(190). Furthermore, the VEGFR2 activation studies do not support the observation that the
increased N-acylurea had no negative effects on proliferation. Therefore, we must conclude that
DS-SILY and N-acylurea stimulate proliferation through mechanisms not elucidated by this
study. However, there are some limitations to our VEGFR2 activation analysis. First, the
experimental design only allows us to compare acute responses to soluble factors, while the
VEGFR2 activation is a highly dynamic process in which a singular time point cannot capture
the nuances of sustained activities likely present due to the known ability of GAGs to sequester
growth factors and function as a controlled release system. Thus there may be other
complexities in the pathway that we cannot account for, and the discrepancy between the
receptor activation data and the biological proliferative response needs to be explored further by
specifically looking at growth factor binding and controlled release, as well as the timedependent levels of downstream second messengers like MAPK and ERK.
3.4.5 Pro-angiogenic Decorin Mimic Targeting: Relative Surface-binding of Molecules to
Extracellular Matrices
Since our proposed therapy is designed to target angiogenic activity to an ischemic
wound site by tethering to extracellular matrix, investigating these binding properties was critical
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to determine whether decorin mimic targeting was altered after conjugation of additional
peptides. The ability of pro-angiogenic decorin mimics to bind to collagen and fibrinogen
coatings was investigated using streptavidin-HRP detection of surface-bound biotinylated
molecules after a 30 minute incubation with a protein-coated surface. The initial experiments
shown in Figure 3-15A demonstrate baseline characterization of DS-SILY4 to collagen I,
matrigel, and fibrinogen surfaces. Previously, our lab has characterized collagen I targeting and
subsequent modulation of collagen fibrillogenesis, critical for providing scarless healing in
incisional wounds (116), by similar decorin mimics DS-SILY20 synthesized with oxidation
chemistry (191). We were also interested in the decorin mimic’s ability to bind other collagens
such as collagen IV, which is important during the re-epithelialization of dermal wounds (192).
In previous cardiovascular applications of DS-SILY20, the decorin mimic was also studied for
anti-platelet activity by binding to injured luminal vascular surfaces in cardiovascular
applications (191), further justifying investigation of its targeting to basement membrane
proteins, such as collagen IV and laminin, and binding to these proteins was studied through
molecule binding to matrigel. Finally, given the role of clotting in the primary stages of wound
healing and dermatan sulfate’s anti-thrombotic activity, the ability of DS-SILY4 to bind
fibrin/fibrinogen was also of interest.
3.4.5.1 DS-SILY4 has higher binding capacity and affinity for collagens I and IV
compared to fibrinogen.
Using standard surface coating procedures for collagen (50 µg/mL) and matrigel (2%),
~7.5 µg/cm2 rat tail collagen I and ~28 µg/cm2 matrigel were allowed to bind to a high bind
plate. Based on Corning’s reported composition of matrigel (60% laminin, 30% collagen IV,
and 8% entactin), the amounts of collagen I versus collagen IV in the standard coating protocols
should be comparable and thus the results of this experiment were assumed to reflect differential
binding of molecules to collagen I versus collagen IV and laminin. Figure 3-15A shows that DSSILY4 bound in a dose-dependent manner to collagen I, collagen IV/laminin, and fibrinogen with
binding capacities of 1.6, 1.1, and 0.30 AU respectively. Figure 3-15A also shows that binding
detection on a plate coated with collagen following our reported protocol was roughly equivalent
to the binding on a commercially available collagen coated plate (Corning Biocoat) up to 1 µM
of DS-SILY4. In the ranges of 1 to 10 µM, DS-SILY4 exhibited a negative binding trend on the
Biocoat plate, likely resulting from preferential association of DS-SILY4 with itself over the
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surface at higher concentrations. A similar downward binding trend was also seen for DS-SILY4
on the collagen-coated plate in the 5 to 10 µM range. Differing collagen surface densities may
account for these observed differences in binding behavior.
While DS is known to bind thrombin as well as heparin cofactor II in regulating fibrin
formation (193-195), it has also been found to bind fibrinogen (196, 197), and therefore our
designed molecule could possess binding capacity for both collagen and fibrinogen. Fibrinogen
surfaces were exposed to ~400 µg/cm2 fibrinogen, but despite this high coating density, the
fibrinogen surfaces exhibited a low level of dose dependent DS-SILY4 binding relative to
collagen I and matrigel surfaces (Figure 3-15A). Therefore, our results show that a DS-based
construct with a collagen I binding peptide, SILY, has greater binding capacity and affinity for
collagens than fibrinogen. The results also support preferential binding to collagen I over other
matrix proteins, as well as some small amount of binding to fibrinogen that could impart some
anti-thrombotic activities. Preliminary investigation of inhibition of fibrin formation by decorin
mimics in vitro did indicate preserved anti-thrombotic activity (data not shown), but these
properties need more thorough exploration in future studies.
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Figure 3-15. Surface Binding of Molecules to Collagen I-, Matrigel-, and Fibrinogen-coated surfaces.
DS-SILY has greater binding capacity for collagen I than matrigel surfaces and exhibits very low binding of fibrinogen
surfaces (A). Conjugation of peg2V or LXW7 increases DS-SILY binding to both collagen I (B) and matrigel surfaces
(C). Peg2V also exhibits intrinsic collagen I (B) and matrigel (C) binding properties even greater than SILY, but
shows a significant drop in collagen binding at concentrations exceeding 0.5 µM. LXW7 conjugation improves
LXW7-DS-SILY collagen I specificity over matrigel (D). Peg2V conjugation increases peg2V-DS-SILY binding to
both collagen I and matrigel.
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3.4.5.2 Peg2V Conjugation to DS-SILY4 Increases Collagen I and Matrigel Binding
Capacity and Synergistically Strengthens Collagen I and Matrigel Binding Affinity
As seen in Figures 3-15B and 3-15C, peg2V conjugation to DS-SILY4 increased binding
to collagen I and matrigel. To determine whether this increase was caused by non-specific b
inding due to greater peptide substitution or intrinsic collagen I affinity, we studied whether
removing the known collagen-binding SILY peptide would still allow for dose-dependent
collagen I binding. Figure 3-15B (green curve DS-(peg2V)2) reveals that, when conjugated to
DS, peg2V does have very high intrinsic collagen I affinity but appears to aggregate more readily
at concentrations above 0.5 µM, represented by a significant drop in binding at high
concentrations. In fact, between the concentrations of 0.05 to 1 µM, DS-(peg2V)2 had the
highest collagen I binding capacity of all the molecules studied (Figure 3-15B), although it was
statistically similar to the 3.2LXW7-DS-SILY4 variant. Interestingly, since DS-(peg2V)2
exhibited higher collagen I binding capacity than DS-SILY4, collagen may have more binding
sites for peg2V than SILY. This is especially significant given that the addition of only 2 peg2V
peptides produced greater binding than 4 SILY peptides, and noting that both molecules were
synthesized with the same amount of EDC and assuming that biotinylated SILY produced a
comparable signal to biotinylated peg2V. This suggests that the amounts of N-acylurea should
be comparable and differences between the DS-SILY4 and DS-(peg2V)2 molecules could not be
accounted for by EDC. However, one possible unaccounted variable is the use of biotinylated
SILY versus biotinylated peg2V for detection of these two molecules. If, for example,
biotinylated peg2V somehow produced an enhanced signal compared to biotinylated SILY, this
would compromise any conclusions made comparing the surface-binding properties of these two
molecules. Notably, Figure 3-15B also demonstrates that DS-(peg2V)2 has a higher affinity for
collagen I than DS-SILY4, while their matrigel binding affinities were similar (Figure 3-15C).
However, it appears that the combination of peg2V with SILY synergistically strengthens
binding affinity to both collagen I and matrigel as (peg2V)2-DS-SILY4 demonstrated the highest
collagen I and matrigel affinities with significantly greater binding at lower concentrations <0.05
µM. The data taken altogether suggests that peg2V exhibits specific collagen I binding even
greater than SILY, but the simultaneous conjugation of both peptides increases collagen I and IV
affinity and reduces molecular aggregation high concentrations.
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3.4.5.3 LXW7 Conjugation to DS-SILY4 Increases Total Collagen I Binding Capacity and
Improves Collagen I Specificity over Collagen IV
As seen in Figures 3-15B and 3-15C, LXW7 conjugation to DS-SILY4 also increased
binding to collagen I and matrigel. Taking a different approach to investigating the effects of
LXW7 on collagen binding, we compared variants with differing degrees of LXW7 substitution.
3.2LXW7-DS-SILY4 had greater binding capacity than 0.8LXW7-DS-SILY4 at all
concentrations and both bound collagen I better than DS-SILY4 alone, suggesting that the
addition of LXW7 increased collagen I binding sites. From Figure 3-15B, addition of LXW7
also improved molecule affinity to collagen I since 3.2LXW7-DS-SILY4 had significantly
greater affinity than 0.8LXW7-DS-SILY4. Most notably, as seen in Figures 3-15C and 3-15D, a
higher LXW7 substitution also improved collagen I specificity over matrigel since 3.2LXW7DS-SILY4 had higher collagen I binding but lower matrigel binding than 0.8LXW7-DS-SILY4.
It is possible that LXW7 does this by more specifically binding collagen I or that it imparts nonspecific collagen I binding and simultaneously hinders matrigel binding by unknown
mechanisms, but biotinylated DS-LXW7 variants (lacking SILY) were not synthesized to rule
out non-specific binding.
3.4.5.4 Prolonged Room Temperature Incubation in 1% BSA Decreases Effective
Molecule Concentrations and Reduces Specificity for Collagen I over Collagen IV
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Figure 3-16. Changes in Surface Binding after Molecule Incubation for 2 weeks in 1%BSA.

After application to the wound bed, it is possible that slow hydrolytic degradation of the
pro-angiogenic decorin mimics over several days could change binding properties and thereby
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cause increased likelihood of diffusing into systemic circulation. To study the hydrolytic
deterioration of binding activity over time, we observed surface binding properties of DS-SILY4
and (peg2V)2-DS-SILY4 after 2 weeks in 1% BSA at room temperature (Figure 3-16 A & B).
This experimental design assumes that differences in binding properties after molecules were
incubated for a prolonged period in 1% BSA were due to hydrolytic degradation of the
molecules rather than interactions with BSA. It was presumed that similar interactions with BSA
would occur when molecules were freshly dissolved (~1 hour in 1% BSA) and when they were
in 1% BSA solution for the 2 week period. From Figures 3-16 A & B, it is clear that both the
collagen I and matrigel binding curves shifted after the 2 week incubation such that higher
concentrations are needed to achieve the same binding, reflected by lower molecule affinities.
However while total binding capacity of DS-SILY4 to collagen I is maintained after partial
hydrolysis, the partially degraded DS-SILY4 had increased total matrigel binding capacity at
concentrations > 0.5 µM. This observation suggests that hydrolytic degradation and/or
interactions with BSA over the 2 weeks not only decrease effective molecule concentration, but
also alters the total number of DS-SILY4 binding sites for matrigel. In contrast for (peg2V)2-DSSILY4, the molecule maintains higher binding capacity for collagen I than matrigel over the full
concentration spectrum and total binding capacities for collagen I and matrigel are unchanged.
Taken together with the observation that peg2V renders intrinsic collagen I and matrigel binding,
the addition of peg2V to DS-SILY4 provides additional collagen binding capacity that maintains
collagen I specificity over matrigel after the 2 week incubation period. However we are unable
to make any conclusions about peg2V degradation. The overall observed concentration shifts
suggest that the effective molecule concentration has decreased after the 2 week incubation,
which could be caused by degradation of the full molecule or hydrolysis of the collagen-binding
SILY peptide. Although more pronounced molecule aggregation after the 2 week incubation
may be a confounding factor, agglomeration alone cannot account for the changes in total
matrigel binding capacity observed for DS-SILY4.
3.4.6

Binding and Activation of VEGFR2

3.4.6.1 Characterization of V Binding Affinity to VEGFR2
As a preliminary assessment of the angiogenic potential of our engineered therapies, we
first assessed the ability of our modified VEGF-mimicking peptide, V, to bind VEGFR2 using
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biolayer interferometry on an OCTET instrument (Pall ForteBio). The steps for biosensor
preparation are diagrammed in Figure 3-17A and a sample binding curve depicted in Figure 317B. We observed concentration-dependent binding of VEGF and V peptide to immobilized
VEGFR2 (Figure 3-17 C & D) with binding curves resembling heterogeneous binding of the
analytes to the receptor. In our initial testing, we found that similar binding curves with greater
signals could also be achieved using 0.1% BSA as a blocking agent, but the blocking was not
sufficient to prevent non-specific binding. Use of 1% powdered milk dissolved in PBS was
required to remove non-specific binding background. The resulting dissociation constants, KD,
were found to be ~0.146 nM and ~80.1 uM for VEGF and VEGF-mimicking peptide V,
respectively. The measured KD for VEGF, an average from 6 curves, is comparable that reported
in literature of 410 pM (198). For V peptide, the KD reported is measured as an average of the 3
lowest concentration curves, since the higher concentration curves did not match the modeled
binding lines shown in red (Figure 3-17D) and exhibited a heterogeneous binding curve (Figure
3-17B). For VEGF, kon was 3.22*106 M-1 s-1 and koff was 3.86*10-4 s-1. The corresponding kon
for VEGF-mimicking peptide was 2.48 M-1 s-1 and koff was 1.75*10-3 s-1. The significantly
higher measured KD for the VEGF-mimicking peptide indicates that its VEGFR2 binding affinity
is multiple orders of magnitude lower than native VEGF and thus significantly higher peptide
concentrations would be needed to exert the same binding responses. As kon is also much larger
but koff is smaller for VEGF, it also appears that VEGF binds quicker and dissociates slower than
the VEGF-mimicking peptide. These binding experiments clearly show measurable differences
in the binding affinity, association, and dissociation kinetics of peptides compared to the full
growth factor. It follows that VEGFR2 activation dynamics likely differ significantly as well.
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3.4.6.2 Characterization of VEGFR2 Activation due to Pro-Angiogenic Decorin Mimics
Prolonged VEGF stimulation elicits a quick increase and rapid decline of VEGFR2
phosphorylation over 30 minutes (Figure 3-18A). After 5 minute treatments, HUVECs showed a
synergistic response to VEGF with peptides QK or V and an even greater potentiation with
DSV4 (Figure 3-18B). Peptides or DSV4 alone did not show significant increases in %
VEGFR2 phosphorylation after 5 minute exposures to treatments (Figure 3-18B). Increasing
treatment time to 30 minutes increased %VEGFR2 phosphorylation marginally and very slowly
over time for both peptides QK and V and all DS-based constructs (Figures 3-18 C & D). It
therefore appeared that binding kinetics of free peptides and DS molecules differed from VEGF,
an observation that is supported by the OCTET binding studies.
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response to constant stimulation by 10 ng/mL VEGF, while peptides and DS-based constructs produce a very slow
low amplitude increase in % phosphorylation over 30 minutes. Subfigure B shows %VEGFR2 activation after
treating HUVECs for 5 minutes with VEGF or DSV4 showing significant synergism. Differences in %VEGFR2
activation from QK synergism compared with V synergism are not statistically significant. Sample n = 3, with
measured values presented as mean ± standard deviation. Bracketed pairs with * denote statistically significant
differences in treatment groups.
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3.5

Conclusion
In completion of the aims of this chapter, we described the design, development, and

characterization of pro-angiogenic decorin mimics. We developed synthetic methods for
peptide-hydrazides and pro-angiogenic decorin mimics, as well as non-destructive quantification
methods to determine degree of peptide substitution. In special consideration for the VEGFmimicking peptides, we ensured that alpha-helical secondary structure was maintained before
and after conjugation. We also ensured that the VEGF-mimicking peptide could bind VEGFR2
in a concentration dependent manner and characterized its binding affinity, association, and
dissociation rates compared to native VEGF. Moreover, we explored how the EDC synthetic
chemistry may produce unintended biological effects, and provided preliminary results for an
alternative DMTMM chemistry. Next, ECM binding properties with special interest in their
ability to target collagen I and matrigel were characterized. These binding properties are
pertinent to the bioactivity experiments explored in chapter 4, where surface-bound molecules
are assessed for angiogenic activity. Finally, we also briefly explored VEGFR2 activation.
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4. ASSESSMENT OF IN VITRO AND IN VIVO ANGIOGENESIS OF
PRO-ANGIOGENIC DECORIN MIMICS

4.1

Preface
Having discussed in detail the developmental synthesis and characterization of pro-

angiogenic decorin mimics along with some preliminary exploration of the molecule’s effects on
receptor activation in Chapter 3, Chapter 4 focuses on assessing in vitro and in vivo angiogenic
bioactivity, with and without VEGF, of two variants of pro-angiogenic decorin mimics
((peg2V)3-DS-SILY4 and 4LXW7-DS-SILY4). We evaluate 1) endothelial cell (EC)
proliferation and migration, 2) two-dimensional EC tubule formation on matrigel embedded with
pro-angiogenic decorin mimics, 3) neovascularization from a chick chorioallantoic membrane
(CAM assay) growing into a collagen scaffold embedded with pro-angiogenic decorin mimics,
reflecting the ability of the scaffold to integrate into existing vasculature, and 4) EC monolayer
permeability. Refer back to Figure 3-2 for the overall breakdown of Chapter 3 and Chapter 4. In
addition to discussing the angiogenic activity of the two variants, our biological results highlight
the importance of peptide presentation (soluble versus bound and varying surface densities) in
affecting bioactivity.

4.2 Introduction
4.2.1

Special Considerations for Preserving Pro-angiogenic Properties of QK
In the introduction to Chapter 3, numerous examples of recent studies were provided

showing that surface-bound QK could exert an angiogenic response, often even greater than the
free QK peptide alone. In solution, free QK is always reported to exert an angiogenic response.
However, it is worth noting that two studies have also revealed that QK presentation in an
immobilized form, specifically at high densities (166, 199), can also elicit anti-angiogenic
effects, perhaps due to the complexities of the VEGF signaling pathway. VEGF receptors
become activated by tyrosine kinase phosphorylation after receptor dimerization (200, 201). As
VEGF molecules preferentially form homodimers, each VEGF within a homodimer binding a
receptor brings two VEGF receptors into close proximity of each other to allow phosphorylation
and activation. The most compelling explanation for the anti-angiogenic property observed in
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some studies of immobilized QK is a proposed phenomenon Koepsel et al. has termed “receptor
pinning” by which a given surface density of QK occupies VEGF receptors in a manner that
prevents dimerization; Koepsel et al. also speculates that very short linkers from QK to the
substrate may exacerbate this “receptor pinning” because short linkers cause the occupied VEGF
receptors to become less mobile (199). These particular studies demonstrate the importance of
characterizing our system and carefully designing moderate surface densities. The proposed
mechanism of receptor pinning also suggests that it is advantageous to use longer peptide linkers
for pro-angiogenic applications.
4.2.2

Special Considerations for Preserving Pro-angiogenic Properties of LXW7
LXW7 peptide was originally developed as a targeting ligand to inhibit αvβ3 integrin and

deliver therapies to cancer cells overexpressing this integrin (202). In these studies, free LXW7
acts as a competitive inhibitor of αvβ3 integrin to block cell binding and angiogenesis (203, 204)
and is proposed to act by down-regulating VEGF and its associated pathways (175, 176). It
follows then that LXW7 is anti-angiogenic in soluble presentation and needs to be surface-bound
to be pro-angiogenic.

4.3 Materials and Methods
4.3.1

Cell Culture

Human Dermal Microvascular Endothelial Cells (HMVEC, Lonza CC-2543) were expanded
according to the manufacturers’ protocol in EGM2-MV media, and passaged at 70-90%
confluence. Cells were cryopreserved in 80% media, 10% sterile DMSO, and 10% FBS. For
experiments, HMVECs were used between passages 6 and 8, and maintained at 37°C and 5%
CO2.
4.3.2

Endothelial Proliferation in Response to Soluble Molecules

HMVECs were seeded at 2000 cells per well in a CellBind® 96-well plate (Corning) using
complete EGM-2MV media. After 24 hours, media was replaced with EBM (serum and growthfactor free) for 4 hours and then replaced with treatments dissolved in EGM-2MV media lacking
VEGF or lacking both FGF and VEGF. After 24 or 72 hours, proliferation was evaluated by an
endpoint MTS assay (CellTiter 96® AQueous One Solution, Promega), by adding 10 µL of 3-
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(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium
(MTS) inner salt reagent to each well, incubating for 4 hours at 37C, and then measuring
absorbance at 490 nm. A standard curve to determine appropriate cell seeding numbers and
correlation of initial cell number to metabolic activity was also performed.
4.3.3

Endothelial Attachment and Proliferation in Response to Surface-bound Molecules

50 µL treatments dissolved in 1% BSA in PBS were added to a Biocoat Collagen I 96-well
plate (Corning) and incubated for 30 minutes at 37C before washing 3 times with PBS to remove
unbound treatment. HMVECs were then seeded in either EGM2-MV media or EGM2-MV
media without VEGF at a density of 1500 cells per well (low cell density) or 8000 cells per well
(high cell density). To evaluate initial attachment, media was aspirated 6 hours after seeding and
exchanged with alamarBlue® cell viability reagent (1:10, 110 µL/well, Molecular Probes) and
incubated for 2.5 hours at 37°C according to the manufacturers’ protocol. 100 µL from each
well was pipetted into a new plate and assayed for fluorescence at 560 nm excitation and 590 nm
emission. Remaining reagent was aspirated and replaced with fresh media and the alamarBlue®
viability assay was performed every 2 days thereafter for 1 week. To control for initial
differences in HMVEC attachment, proliferation data is presented as the alamarBlue®
fluorescence signal normalized to the signal at 8 hours.
4.3.4

Endothelial Migration

ORIS 96-well plates (Platypus technologies) were coated with 50 µg/mL human fibrillar
collagen I (Chronolog) overnight at 4°C. Wells were rinsed 3x with PBS and left to air dry
under UV for 1 hour before inserting ORIS silicone stoppers and seeding HMVECs at 8000 cells
per well around the stoppers. Cells were allowed to grow to confluence for 48 hours before a 30
minute incubation with 4 µg/mL mitomycin C (Sigma) to halt proliferation. After removal of
ORIS stoppers, cells and the collagen-coated surface were incubated with 10 µM of DS-SILY
constructs dissolved in EGM-2MV without VEGF for 15 minutes. The treatments were removed
and replaced with growth media (EGM-2MV without VEGF) for 48 hours before staining with
10 µM CellTracker Green (molecular probes) and fluorescent imaging on a Keyence BZ-X700
microscope. Fluorescent images were quantified by pixel area analysis on ImageJ.
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4.3.5

Endothelial Tubulogenesis

Reduced growth factor Matrigel (Corning) was mixed with treatments on ice to obtain the
final desired concentrations (10, 20, and 30 µM) within the gel and distributed to Ibidi
angiogenesis µ-slides at 10 µL per well to polymerize at 37°C for 30 minutes. HMVECs were
seeded at 7500 cells per well in reduced growth factor media (EGM-2MV lacking FGF, VEGF,
and IGF supplements). After 8 hours of incubation, cells were stained with 2 µM calcein AM
and imaged on a Keyence BZ-X700 microscope. Image analysis tubule quantification was
performed by AngioQuant software with a prune factor of 25 to remove artefacts from cellular
debris (205).
4.3.6

Ex Ovo Chick Chorioallantoic Membrane (CAM) Assay

The ex ovo CAM assay and vessel quantification was performed similarly to previously
established protocols for treatments eluting from alginate gels (206-208) and for de novo vessels
invading collagen gels (209, 210). Fertilized Hyline eggs obtained from the Avian Facility at
UC Davis were incubated at 37°C for 72 hours with 6 rotations per day at 80% humidity in a
Grumbach egg incubator. On day 3, eggs were cracked open into disinfected weighboats (VWR)
and covered with lids from square petri dishes (Fisher), and the embryos developed over a week
in the incubator. On day 10, treatments encapsulated in collagen I gels were gently placed on the
developing CAM. For experiments involving treatments freely eluting from the collagen gels,
100 µL of gel was polymerized in a 10 mm diameter rubber mold against a sterilized glass slide,
and 1 treatment gel and 1 control gel was placed per CAM. Gels were imaged using a 12
megapixel camera. The number of vessels in a 2 mm radius immediately surrounding the gel
was manually counted in imageJ immediately after placement and 24 hours later to determine
changes surrounding vessels. The change in vessels over 24 hours for treatment gels were
normalized to the respective change in the control gel on the same developing embryo. For
experiments studying vascular invasion into collagen gels, 30 µL collagen I gels with an
embedded 3 mm x 3 mm nylon mesh (Fisher) were used. 4-5 gels were placed on each CAM,
with 2-3 treatment gels of the same type and 2 blank gels as internal controls to correct for
embryo variability. In some embryos, the nylon meshes were dyed to improve visualization of
the mesh and vessels growing into the gel. Large (4 cm x 10 cm) nylon meshes were dyed by
reacting in 226 mL of a 77 mM acetic acid (Sigma) solution with 10 drops of green food coloring
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(McCormick) or 250 µL of 3 mg/mL Evans blue (Alfa Aesar) at 121°C for 15 minutes in an
autoclave, and then cut to 3 mm x 3 mm squares for embedding. Gels were imaged daily
through a Dino-Eye AM7025X camera installed on a stereomicroscope; for images more than 2
days after gel implantation, 0.25 mL PBS was pipetted on top of gels to help visualize vessels.
On day 16, 0.1mL of 1mg/mL RITC-dextran (70 kDa, Sigma) or Evans blue was injected into
the CAM vasculature using a 30G needle, and the membrane was cut away from the embryo and
placed in a petri dish for brightfield and fluorescent imaging. To quantify vascularity within the
gel between 72-96 hours after gel placement, two independent observers scored each gel for the
proportion of grids within the mesh that showed positive vessel growth, as described in Zijlstra
et al. (210).
4.3.7

Endothelial Monolayer Permeability

Using EGM2-MV media lacking VEGF, HMVECs were seeded onto 3 µm pore 24-well
transwell inserts (Corning) at 10,000 cells per insert. The following day, an additional 50,000
cells were seeded to each insert and allowed to grow for another 24 hours. Media was then
removed and replaced with 0.5 mL media to the bottom well and 0.1 mL of treatment media to
the insert for 10 minutes. Treatment was removed and 0.3 mL of 1mg/mL RITC-dextran in
media was then added to each transwell insert and allowed to permeate for 30 minutes. Sample
permeate was then assayed on a SpectraMax M5 plate reader for fluorescence (ex: 570 nm; em:
590 nm). RITC-dextran solutions and sample permeates were then aspirated and replaced with
another 0.1mL of treatment media in the transwell insert and 0.5mL media in the bottom
chamber. This procedure was repeated daily over 4 days. Treatments were also compared to
inserts with cells removed by rubbing away with a pipette tip to determine the barrier efficacy of
the monolayer and the degree of increased permeability.
4.3.8

Statistical Analysis

All quantitative data is presented as mean ± standard deviation, and statistical significance
was evaluated by ordinary one-way ANOVA using post-hoc Dunnett’s or Tukey’s tests for
multiple comparisons with values p < 0.05 denoted as significant.
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4.4

4.4.1

Results and Discussion
HMVECs Attachment to Surface-bound Molecules

4.4.1.1 Peg2V Conjugation to DS-SILY4 Decreases Cell Attachment
Microvascular endothelial cell adhesion to surface-bound molecules was studied for its
relevance to endothelial recruitment in the wound healing process. Figure 4-1 demonstrates that
at low cell densities, both 1 µM and 10 µM DS-SILY4 surface treatments caused a slight 7%
decrease in HMVEC attachment compared to a BSA blocked collagen surface (untreated
control), although the decrease was only statistically significant at 10 µM (asterisks indicate
treatments that were statistically different from DS-SILY4 control). This was a significant
finding since our lab has not previously investigated the effects of decorin mimic-coated
collagen surfaces on cell attachment. Since DS-SILY4 binds and masks collagen fibrils (116,
191), decreased adhesion is likely due to a decrease in exposed collagen and therefore reduced
cell adhesion sites. Surprisingly, both 1 µM and 10 µM (peg2V)3-DS-SILY4 caused an even
greater 15% decrease in HMVEC attachment compared to DS-SILY4 alone (Figure 4-1). This
additional decrease could be attributed to increased surface concentrations of (peg2V)3-DSSILY4 due to higher surface binding discovered through the binding experiments (Figure 3-14B),
thereby masking the underlying collagen more effectively and further decreasing adhesion sites
for cells. Alternatively, it is possible that the conjugated peg2V peptide directly prevents cell
attachment by unknown mechanisms. Although soluble QK has been shown to improve
endothelial proliferation in numerous studies (159, 160, 163, 166), its effects on endothelial
attachment have not been explicitly studied. Wang et al.’s study shows no significant effects of
matrix-bound QK on endothelial adhesion (162) and Koepsel et al.’s study highlights one
instance where immobilized QK exhibited anti-angiogenic effects and specifically decreased
endothelial attachment, as it had no effects on fibroblast adhesion (199). Further adhesion
studies of other cell types lacking significant levels of VEGF receptors are necessary to
determine whether our observations result from VEGF receptor interactions or simply due to
reduced exposed collagen.
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Figure 4-1. HMVEC Attachment to Surface-bound Molecules with Varied Surface Treatment Concentration
(A & B) and Varied Cell Seeding Density (C).
HMVECs were seeded at a low density of ~4500 cells/cm2 (optimal for proliferative assays) on collagen I surfaces
treated with either 1 uM or 10 uM molecules in 1% BSA, allowed to attach for 6 hours, and then metabolic activity
was assessed by AlamarBlue activity (n = 3). The responses with 1 uM and 10 uM surface treatments were
comparable, which was to be expected due to approximate saturation of the surface at 1 uM. In a follow-up study
(subfigure C), cells were seeded at a nearly confluent, > 6-fold higher density of ~28500 cells/cm2 (optimal for
migration assays) on collagen I surfaces treated with 10 uM molecules in 1% BSA and similarly assessed for
attachment with AlamarBlue (n ≥ 8). * indicates a statistically significant difference compared to DS-SILY4
control. Bars labeled with the same letter (A, B, or C) are statistically equivalent to each other.

4.4.1.2 High LXW7 substitution to DS-SILY4 increases cell adhesion especially at high cell
seeding densities, but low LXW7 substitution decreases cell adhesion
To determine the effects of LXW7 conjugation on cell adhesion, multiple variants with
varying degrees of LXW7 substitution were investigated. A low LXW7 substitution of 1 caused
a significant 18% decrease in cell adhesion at both 1 µM and 10 µM concentrations similar to the
peg2V addition; however, increasing LXW7 substitution caused a trending increase in HMVEC
attachment, with the greatest positive effect at 3.5 LXW7 (Figure 4-1 A and B). At both 1 µM
and 10 µM, it appears that a threshold substitution degree of at least 2 LXW7 is required to
prevent negative effects on attachment. Although cell adhesion was similar between the 1 and
10 µM concentrations for all treatments, a 10 µM concentration was required to observe that a
moderate degree of substitution between 3 and 4 provides an optimal attachment level
significantly greater than DS-SILY4 by 8% and comparable to attachment to an untreated
collagen I surface blocked with 1% BSA (Figure 4-1B). This phenomenon could be explained
by significantly higher molecule binding to the collagen surface and masking exposed collagen
or by repulsive effects from DS’ negative charge. We also observed that conjugation of 1 LXW7
leads to lower cell attachment that could be compensated by increased LXW7 substitution that
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either directly facilitated increased cell attachment or improved cell survival by decreasing
apoptosis. Given LXW7’s role facilitating cell adhesion through integrin-binding, it was
surprising that increased LXW7 substitution beyond 3.5 did not significantly increase cell
attachment when cells were seeded sparsely for proliferation assays (~4500 cells/cm2 as
recommended for HMVEC expansion by Lonza), since other groups have observed increased
endothelial attachment to LXW7-coated surfaces (149). The discrepancy in our observations
might be attributed to the much lower surface densities of LXW7 in our studies due to low
LXW7 substitution on DS-SILY. Furthermore, cell attachment is assessed after a relatively long
period of 6 hours, whereas studies by other groups assessed attachment to LXW7 surfaces after <
2 hours incubation (149). It is therefore possible that differences in cell attachment that can be
observed at earlier time points, indicating the speed of attachment, are not captured in our study.
Nevertheless, at our relatively low LXW7 surface densities, increasing the cell seeding density
more than 6 fold (~28,500 cells/cm2) to confluence was able to reveal the expected increases in
cell binding in response to 4LXW7-DS-SILY4 with restored HMVEC attachment comparable to
an unblocked collagen I surface (Figure 4-1C). Since the cell seeding density needed to be
confluent to see increased cell attachment on our surface, the LXW7-induced increases in cell
attachment and/or survival must be dependent on direct cell-cell interactions, although further
investigation is needed to elucidate the mechanisms by which cell-cell communication in
combination with integrin signaling improved cell survival/attachment.
4.4.2

HMVEC Proliferation in Response to Soluble Molecules and Surface-bound
Molecules

4.4.2.1 Assay Selection for Assessment of Cell Proliferation
Although both the MTS and alamarBlue assays are indicative of total metabolic activity
rather than actual cell number, direct analysis of discrepancies between metabolic versus DNA
assays have suggested that metabolic assays can be appropriate for high throughput analysis,
taking into account their limitations of potentially overestimating proliferation compared to DNA
quantification (211). One of the advantages to using the non-endpoint metabolic assay
alamarBlue for the study of cell response to surface-bound molecules was the ability to follow
multiple samples overtime while reducing the overall amount of treatment needed. This was
especially beneficial in our studies since our treatments and peptides were synthesized in small
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batches in our lab. In the experiments studying response to soluble molecules, the alamarBlue
was not suitable because the solution needed to be replenished after every time point, thus
requiring a greater overall amount of treatment. Proliferation tests for soluble molecules were
therefore assessed with MTS and confirmed by direct Cyquant DNA analysis (data not shown).
4.4.2.2 Short PEG linker in peg2V peptide is important in maintaining proliferative
bioactivity after conjugation.
Initial investigation of proliferative bioactivity using an endpoint MTS metabolic assay
revealed a trending increase in HMVEC proliferation in response to constant 24 hour and 72
hour stimulation by soluble DS(peg2V)3 and (peg2V)3-DS-SILY4 but not DSV3 when compared
to DS and DS-SILY4 alone (Figure 4-2). These same trends were seen in media lacking both
VEGF and FGF. First, the experiment demonstrated that conjugated peg2V peptide was
responsible for the observed increased proliferation, since 10 µM soluble (peg2V)3-DS-SILY4
also significantly increased proliferation compared to 10 µM soluble DS-SILY4. Next, the
trending increase in bioactivity for DS(peg2V)3 compared to DSV3 suggests that the longer
spacer between the active QK sequence and the DS backbone improved the proliferative
response, perhaps by allowing better access for peptide binding to the VEGF receptor or by
better conserving the α-helical secondary structure. However, any differences in the secondary
structure are very slight, as demonstrated by our CD analysis (Figure 3-9 A and E). The slightly
increased bioactivity for (peg2V)3-DS-SILY4 over DS(peg2V)3 may be accounted for by higher
local concentrations around the cell when bound to secreted collagen and other matrix molecules
(assessed in binding experiments Figure 3-14) and could therefore exert a more potent
proliferative response. Since the longer peptide spacer was found to be important for improving
conjugated VEGF-mimicking peptide bioactivity, all further studies of bioactivity exclusively
used peg2V rather than V peptides. The LXW7-conjugated variants were not tested in the
soluble proliferation assay, since LXW7-DS-SILY4 variants required surface binding to enact
proliferative bioactivity through integrin-binding.
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Figure 4-2. HMVEC Proliferation in Response to Soluble VEGF-mimicking Treatments.
HMVECs showed trending increases in proliferation after 72 hours of treatment with soluble VEGF-mimicking
treatments DSV3, DS(peg2V)3, and (peg2V)3-DS-SILY4. Since DS(peg2V)3 was more effective than DSV3, the
extra PEG linker is important for preserving bioactivity of the VEGF-mimicking peptide after conjugation to DS.
Sample n ≥ 4, with measurements representing mean ± standard deviation. * denotes statistically significant
differences between bracketed groups. Note that not all groups are explicitly compared.

4.4.2.3 Surface-bound decorin mimics significantly enhance endothelial proliferation
Both soluble and bound forms of molecules would be present in a dynamic equilibrium in
this initial experimental design and the two forms may produce differing effects, and thus we
sought to investigate the effects of bound molecules alone. Furthermore, the bioactivity of a
collagen-bound form would more directly reflect the application of a targeted pro-angiogenic
therapy in a chronic wound. To investigate the effects of surface-bound molecules, collagen
surfaces were first incubated with treatments to bind and then washed thoroughly to remove any
unbound molecules before seeding and following cell growth every other day for a week with
media replenished every other day. To control for differences in initial cell number due to
surface effects on cell attachment, signals were normalized to the signal 8 hours after seeding.
As observed by Scott et al. (190) for a similar but oxidized DS-SILY20 molecule, DSSILY4 surface treatments significantly improve endothelial proliferation compared to untreated
collagen alone. The effects of 1 µM DS-SILY4 were only statistically significant over no
treatment when compared in media lacking VEGF, but 10 µM DS-SILY4 significantly improved
proliferation in media with and without VEGF (Figure 4-3). The effects of 1 and 10 µM
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concentrations were very comparable, because although 10 µM DS-SILY4 improved
proliferation over 1 µM by day 6 in media with VEGF, 1 µM DS-SILY4 was equally as effective
as 10uM during the first 4 days of growth. The relative similarity between the 1 and 10 µM DSSILY4 concentrations could be expected given the apparently saturated collagen I-binding
plateau found in the surface binding experiments (Figure 3-14).
4.4.2.4 Peg2V conjugated to DS-SILY4 potentiates VEGF-mediated proliferation
A peg2V conjugated DS-SILY4 variant was investigated in 2 concentrations to observe
proliferative effects. In media lacking VEGF, (peg2V)3-DS-SILY4 did not have any significant
proliferative effects, although the higher 10 µM concentration showed a trending improvement in
proliferation (Figures 4-3 A & B). In contrast, (peg2V)3-DS-SILY4 surface treatment
significantly improved proliferation over DS-SILY with VEGF supplementation, indicating an
apparent synergistic effect of the conjugated peg2V with VEGF (Figures 4-3 C & D). At 1 µM,
(peg2V)3-DS-SILY4 surface treatment was as effective as the 10 µM treatment, both resulting in
~9-fold increase after 144 hours of growth; however, the 1 µM more effectively potentiated
VEGF activity compared to 10 µM, providing a 27% increase in proliferation over the 1 µM DSSILY4 control versus an 18% increase over the 10 µM DS-SILY4 control. In summary, our
results show that (peg2V)3-DS-SILY4 were not effective on their own, but significantly
potentiated VEGF activity.
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Figure 4-3. HMVEC Proliferation in Response to Surface-bound VEGF-mimicking (peg2V)3-DS-SILY4.
DS-SILY4 alone produces a proliferative increase in media with and without VEGF. Although conjugated peg2V on
(peg2V)3-DS-SILY4 does not provide additional proliferative activity in media lacking VEGF, this pro-angiogenic
decorin mimic shows greater proliferation over DS-SILY4 in the presence of VEGF supplementation, suggesting
that peg2V exhibits synergistic proliferation with VEGF.

4.4.2.5 Surface densities of LXW7 conjugated to DS-SILY4 impact the ability of LXW7DS-SILY4 variants to enhance endothelial proliferation, suggestive of optimal
bioactivity dependent on integrin clustering
Multiple LXW7-DS-SILY4 variants with differing degrees of substitution were tested to
determine the effect of LXW7 density on endothelial proliferation, since varying RGD surface
densities and patterning are known to affect integrin binding conformation and activation
(212)and can thereby have significant effects on subsequent VEGF receptor clustering and
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activation. Figure 4-5 presents cross-sectional information from Figure 4-4 at the 144 hour time
point for ease of interpretation; the 144 hour time point was chosen to show the greatest
differences in responses to treatments before change in metabolic activity appears stagnant
perhaps due to cells reaching confluence at 192 hours with media supplemented with VEGF
(Figures 4-3 and 4-4).
When surfaces were treated with low 1 µM molecule concentrations, increasing LXW7
substitution produced unexpected bimodal trends. In media lacking VEGF (Figure 4-5A),
HMVECs exhibited a bimodal proliferative response to increasing LXW7 substitution with
optimal peaks at 2-3.5 and 5.5 LXW7. A similar bimodal shape, but somewhat left shifted, was
also seen with VEGF supplementation, peaking at 1 and 4-5.5 LXW7 (Figure 4-5C). The left
shift in the presence of VEGF can be expected since it indicates that lower LXW7 substitutions
were now able to produce greater responses with the help of VEGF. The bimodal shape suggests
that the very low surface LXW7 density present at 1 µM surface treatments caused complex
cellular interactions both in the absence and presence VEGF. It is possible that at our very low
surface densities, direct LXW7 integrin activation is insignificant such that response over the
bioactivities of the DS-SILY4 alone are negligible unless the LXW7 peptide density is in a
configuration that promotes potentiated responses. This type of response trend could be at least
partially explained by optimal LXW7 surface densities reported in literature for integrin
activation, taking into account direct ligand activation as well as additional integrin clustering
effects that strengthen downstream signaling (213) and interactions with actin fibers (214-216).
Groups of 3 ligated integrins, spaced within 40-60 nm of each other (213, 217), have been
reported to form an activated integrin cluster that acts synergistically through focal adhesions
and cytoskeletal complexes (215). In fact, clustered integrin spacing induced by small groups of
RGD has been shown to strengthen cell adhesions and promote higher cell motility than
equivalent homogeneous RGD densities (213, 218-220). Given that dermatan sulfate
components of in vivo proteoglycans have been reported at 40-70 nm in length (221), it is likely
that LXW7 peptides conjugated to a single DS molecule would form an activated integrin
cluster. Our data therefore suggests that an optimal substitution of approximately 3 (or multiples
of 3) LXW7 per DS may promote optimal proliferative bioactivity through integrin clustering.
While the low concentration surface treatments exhibited bimodal responses, higher
concentration treatments showed a more straightforward single optimal LXW7 substitution and
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positive effect even at 1 LXW7 per DS-SILY4 (Figure 4-5B). At 10 µM without VEGF (Figure
4-5B), all substitutions less than 5.5 were able to significantly increase HMVEC proliferation
with the most activity optimal at 3.5 LXW7. It is possible that the higher concentration surface
coating enabled direct integrin activation. Interestingly, these variants at 10 µM were as
effective as 10 ng/mL VEGF supplementation, causing a 6-fold increase in proliferation, and the
3.5 LXW7 variant appeared to be even more effective than 10 ng/mL VEGF at an 8-fold increase
(Figures 4-5 B & D). At 5.5 LXW7 without VEGF (Figure 4-5B), there is an unexpected drop in
molecule activity that cannot be explained, but this variant is synergistically effective in the
presence of VEGF and appears to take on similar properties as the peg2V-conjugated variant.
Since we observed that the 5.5 LXW7 variant was highly effective at the 1 µM concentration,
but appears to lose direct efficacy at the 10 µM concentration, perhaps the unexpected effects
can be accounted for by a desensitization response.
With VEGF and 10 µM treatments (Figure 4-5D), all degrees of substitution below 5.5 were
statistically equivalent to DS-SILY4, but 5.5LXW7-DS-SILY4 showed significantly increased
HMVEC proliferation over the DS-SILY4 control. Based on this data, LXW7 synergy with 10
ng/mL VEGF only appeared to be present for the 5.5LXW7-DS-SILY4 variant. The statistical
equivalence of DS-SILY4 with all lower LXW7 substitutions suggests that the 10 ng/mL VEGF
tested masked the effects of low LXW7 substitution and therefore was too high to tease out
synergistic effects. Experiments with lower VEGF concentrations may be necessary to further
examine any synergistic effects of the low LXW7 substitution variants. Taken altogether, the
results indicate that at 10 µM, lower LXW7 substitutions, optimal at 3.5, provide significant
proliferative bioactivity without exogenous VEGF, while high LXW7 substitution variants may
not be effective alone but are more effective at potentiating VEGF.
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Figure 4-4. HMVEC Proliferation in Response to LXW7-DS-SILY variants.
Cell growth appeared to be exponential until 144 hours. Due to the plateauing growth at 192 hours, indicating that
the cells were reaching confluence and/or cell density was inhibiting cell metabolism, statistical analyses of
differences between groups were performed on measurements from the 144 hour time point, and results are depicted
in Figure 4-5. Sample n = 3.
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Figure 4-5. 144 hour HMVEC Proliferation in Response to Surface-bound Treatments.
Figure 4-5 is a cross-sectional representation of Figure 4-4 showing treatment response after 144 hours of exposure,
providing ease of interpretation. Sample n = 3, with measurements presented as mean ± standard deviation.

4.4.3

HMVEC Migration Responses to Surface-bound Molecules (ORIS assay)
Migration responses were explored with and without the application of the anti-

proliferative agent mitomycin C (MMC) in the ORIS assay to study closure of a circular breach
in a confluent endothelial monolayer. Without MMC, the gap closure could be accounted for by
both proliferation and migration over the 48 hour assay. With MMC, gap closure was attributed
to migratory effects alone.
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When cells were exposed to MMC in the absence of VEGF, Peg2V and LXW7
conjugated to DS-SILY4 both significantly stimulated endothelial migration more than DSSILY4 alone (Figure 4-6). Since the untreated surfaces exhibited a significant increase in gap
closure without MMC, normal proliferation must have a significant role in gap closure (Figure 46). Without MMC treatment, there were no statistically significant differences in cell coverage
between the variants, although the 4LXW7-DS-SILY4 stimulated slightly greater cell coverage
(not statistically significant). The results also show that while the gap closure was significantly
higher for DS-SILY4 when MMC was removed, gap closure was statistically similar for
(peg2V)3-DS-SILY4 with and without MMC (Figure 4-6). Moreover, the gap closure was only
slightly increased for 4LXW7-DS-SILY4 when MMC was removed (Figure 4-6). These
differences in monolayer closure with and without MMC suggest that the gap closure due to DSSILY4 is primarily a proliferative response, while coverage from (peg2V)3-DS-SILY4 was from a
migratory response and 4LXW7-DS-SILY4 had important contributions from both migration and
proliferation. We also note that the migration data without MMC closely matched the observed
48 hour proliferative responses to surface-bound molecules discussed previously in our study
(Figure 4-5B); in the absence of VEGF, (peg2V)3-DS-SILY4 stimulated proliferation about the
same degree as DS-SILY4 over an untreated collagen surface, while 4LXW7-DS-SILY4 was able
to produce a greater proliferative response.
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Figure 4-6. Area of Cell Coverage (Normalized to DS-SILY4) after 48 hours of HMVEC Migration in
Response to Surface-Bound Treatments.
With anti-proliferative MMC, both pro-angiogenic decorin mimic variants elicit a significant migratory response
compared to DS-SILY4. Without MMC, cell proliferation accounts for a significant amount of gap closure such that
almost all treatments produce approximately the same response. The LXW7-conjugated variant exhibits a trending
increase in gap closure even when proliferation is not inhibited. Sample n = 4, with measurements presented as
mean ± standard deviation.

4.4.4

HMVEC 2D tubulogenesis in response to matrigel embedded molecules
In vitro matrigel tubulogenesis assays revealed that treatments embedded within gels at a

10 µM concentration had no significant effects on HMVEC tubule number compared to the
untreated controls (Figure 4-7). However, tubule length, size, and number of junctions were
significantly decreased (Figure 4-7). Increasing the embedded treatment concentration to 20 µM
and 30 µM resulted in increased tubule number but also exhibited trending decreases in length,
size, and junction number (Figure 4-7) and these effects were more pronounced with proangiogenic peptide conjugation to DS-SILY4. Since this assay evaluates the responses of cells
seeded on top of the gels, the data suggests that the 10 µM concentration may not present an
adequate surface concentration to elicit a detectable response in tubule number. Given the
proliferation data (Figures 4-2 through 4-5) and the fact that the tubule number increases, the
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shorter, thinner, and less branched tubules that form in response to the decorin mimics are
unlikely to reflect anti-angiogenic properties; anti-angiogenic treatments cause reduction in all
parameters including tubule number. Some limitations of the matrigel assay may convolute the
interpretation of our results. While the rapid time course of the matrigel assay with tubules
forming within a few hours and then regressing after 12 hours allows for quick screening of
angiogenic factors, it may only reflect very acute cellular changes and their corresponding
immediate effects on tubule formation. One possible explanation for our findings is that the
decorin mimics promote accelerated tubule formation and regression such that regressing tubules
were assessed at 8 hours. This tubulogenic response of earlier tubule formation and regression
was observed by Leslie-Barbick et al. for HUVECs within PEG hydrogels with tethered QK
(163). To fully assess this effect, dynamic analysis of tubule formation over time would be
necessary. Despite the limitations of our study, it was clear from the matrigel assay that the
vascular networks exposed to pro-angiogenic decorin mimics differed in structure compared to
untreated controls. Further investigation of longer time-scale 3D in vitro tubulogenesis within
collagen gels would provide more meaningful insight into the structural differences in
tubulogenesis induced by the engineered pro-angiogenic decorin mimics.
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4.4.5

Changes in chick chorioallantoic membrane vascularization in response to collagen
gels: eluted vs. embedded tethered molecules

4.4.5.1 Free VEGF-mimicking peptides eluted from collagen gels stimulate acute CAM
angiogenesis, while the free integrin-binding LXW7 peptide hinders surrounding
vessel formation
Figure 4-8 shows that 100 µM free V and QK peptides had comparable vasculogenic
activity to each other and to 2 µg/mL VEGF-A, stimulating acute increases (30-50% compared
to matched control gels on the same egg) in the number of blood vessels in a 2 mm radius
surrounding implanted 10 mm diameter gels after 24 hours (n ≥ 5). In contrast, elution of 100
µM LXW7 from collagen gels either decreased or caused no changes in surrounding vessel
growth after 24 hours (Figure 4-8 shows a decrease that is not statistically significant). The lack
of increased vascularity in response to free LXW7 seen here suggests that the LXW7 peptide
needs to be surface-bound to promote angiogenesis. This result is supported by other studies
where free LXW7 acts as a competitive inhibitor of αvβ3 integrin to block angiogenesis (203,
204) and is proposed to act by down-regulating VEGF and its associated pathways (175, 176).
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Figure 4-8. Normalized % Change in CAM Blood Vessels over 24 hours in Response to Elution of Soluble
Factors from Collagen I Gels.
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VEGF-A, QK, and V eluting from collagen gels all cause increases in blood vessels surrounding the collagen gels,
while LXW7 exhibits a decrease or no change in surrounding vessels over 24 hours.

4.4.5.2 Peg2V conjugation to DS-SILY4 significantly increases vascularization into
collagen I gel implants
Both 10 µM and 20 µM DS-SILY4 showed a very slight increase in gel vascularity that
was not statistically significant over the blank controls (Figures 4-9 A top row, B, & C).
However, Figure 4-9D demonstrates that 10 µM gel-embedded (peg2V)3-DS-SILY4 significantly
increased the vascularized area within the gel compared to matched blank controls by day 4 after
implantation. Since 10 µM (peg2V)3-DS-SILY4 already showed a significantly improved
vascular response, the 20 µM concentration was not investigated. As can be seen in the
representative vascularized gel images (Figure 4-9A), new vessels invaded the collagen gels in a
radial fashion with many vessels going towards and then away from the center of the
transplanted gel. Under high magnification through a stereoscope, rapidly flowing red blood
cells were apparent within the invading capillaries with directional flow indicative of the
presence of both new arterioles and venules (data not shown).
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Subfigure A displays representative images of vascularized gels with 10 µM treatments compared to their organism-matched control gels, with vascularization
scores (scored by two independent observers) indicated in the upper right corner of each image. Subfigures B-F show the quantitative results for treatments.
Peg2V3-DS-SILY4 was able to significantly increase vascularization into the treatment-embedded collagen gel. LXW7-DS-SILY4 treatment was able increase
vascularization as well, but also appeared to increase vascularization of organism-matched controls. 10 µM DS-SILY4: 8 control gels and 8 treatment gels over 4
chicken embryos; 20 µM DS-SILY4: 3 control gels and 4 treatment gels over 2 embryos. 10 µM (peg2V)3-DS-SILY4: 10 control gels and 10 treatment gels over
5 chicken embryos. 10 µM 4LXW7-DS-SILY4: 8 control gels and 8 treatment gels over 4 chicken embryos; 20 µM 4LXW7-DS-SILY4: 3 control gels and 4
treatment gels over 2 embryos.
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4.4.5.3 LXW7 conjugation to DS-SILY4 increases vascularization into collagen I gel
implants to a similar degree as (peg2V)3-DS-SILY4, but also increases
vascularization into organism-matched blank control collagen gels
Both 10 µM and 20 µM 4LXW7-DS-SILY4 embedded gels caused a large increase in
vascularized gel area, but not statistically significant than the organism-matched blank controls
(Figures 4-9 E & F). In fact, 10 µM and 20 µM 4LXW7-DS-SILY4 treatments produced almost
identical gel vascularization results (Figures 4-9 E & F). Interestingly, the proportion of
vascularized gel area in 4LXW7-DS-SILY4 treated gels was similar to that seen for (peg2V)3DS-SILY4 treated gels, but the organism-matched blank controls exhibited an trending increase
in vascularity compared to blank controls on eggs treated with DS-SILY4 and (peg2V)3-DSSILY4 (Figures 4-9 E & F compared with B & C). Since the increase in the blank controls was
not present in the DS-SILY4 or (peg2V)3-DS-SILY4 treated eggs, it is more likely that this
unexpected increase in the blank control gels results from an LXW7-induced a systemic response
perhaps by release of angiogenic factors into the blood circulation rather than 4LXW7-DS-SILY4
releasing from the collagen gel.
4.4.5.4 New vasculature within collagen gels exhibit increased vascular permeability
regardless of treatment
Vascular permeability was qualitatively assessed by high molecular weight RITC-dextran
intravascular injection through fluorescent imaging of the ex ovo CAM model. In an attempt to
better visualize new vasculature invading the implanted collagen gels, we injected ~100 µL 1
mg/mL high molecular weight fluorescent dextran (70 kDa RITC-dextran) into the CAM vessels
7 days after transplantation, cut out integrated collagen gels and surrounding membrane, and
imaged with fluorescence microscopy. For proof-of-concept, control CAMs without
transplanted gels were injected and imaged with this method and demonstrated that the
fluorescent dextran reasonably represented the vasculature without leaking outside the vessels
(Figure 4-10A). In our studies, both treatment and blank collagen gels showed diffuse red
fluorescence in all eggs (Figure 4-10B). This fluorescent signal was not present in blank
collagen gels not exposed to RITC-dextran (data not shown). Since all the collagen gels
exhibited some degree of leakiness measured by the RITC-dextran fluorescence, it is difficult to
infer the permeability effects of the collagen-bound treatment molecules. Injection of 100 µL of
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a 2% w/v Evans blue in PBS for better visualization of extravasate suggested that while all the
collagen gels had some accumulation of the blue dye, the (peg2V)3-DS-SILY4 gels looked darker
indicating increased vascular permeability in surrounding vessels (Figure 4-11). Due to the low
yields of successful injection distributing fully through systemic CAM circulation, determined by
a color change in all visible vessels, sufficient data was not acquired to make conclusions
through the Evans blue vascular injection method. Further studies increasing the number of eggs
and gels analyzed are needed to determine in vivo permeability.
B

With mesh

CAM vascu lar imaging by fluorescent dye injection
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Figure 4-10. Fluorescent vascular imaging of CAM by injection of high molecular weight RITC-dextran.
Subfigure A shows vascular network highlighted in a control CAM without any gel, while subfigure B depicts CAM
vascular networks with embedded collagen gels with and without embedded nylon mesh and/or pro-angiogenic
decorin mimic treatments. Bright red signal within the collagen gels suggests hyperpermeable vasculature in both
control and treatment gels.
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injection of 20mg/m l Evans blue

II

Figure 4-11. Permeability of new vessels inside the embedded collagen gel assessed by injection of 20 mg/mL
Evan’s Blue.
Pilot studies investigating in vivo permeability in the CAM model show that new vasculature induced by peg2V3DS-SILY4 may be hyperpermeable due to increased extravasation and accumulation of Evans Blue at these
treatment gel sites.

4.4.6

Effects of soluble VEGF-mimicking molecules on HMVEC monolayer permeability
(Transwell)
Given that the CAM assay suggested that the tested molecules may be altering vascular

permeability and that VEGF is also known as vascular permeability factor and is hence widely
known to increase vascular permeability (222), we were interested in the effects of VEGFmimicking peptides on endothelial permeability in comparison to VEGF. Multiple studies
investigating endothelial permeability by various methods have shown that VEGF induces
permeability in a transient, highly time-dependent manner with significant effects seen within 10
minutes to 1 hour of VEGF stimulation and changing over multiple days (222), although the
specific dynamics varied depending on measurement method and endothelial cell type . We
therefore followed treatments after 10 minutes through 3 days, although it is worth noting that
our experimental method effectively investigated permeability effects after a series of repeated

101
bolus treatments of soluble molecules on a HMVEC monolayer. The transwell results in Figure
4-12A demonstrate that the seeded HMVECs indeed formed a monolayer significantly
decreasing permeation of the 70 kDa RITC-dextran compared to wells with no cells, while
Figures 4-12 A and C indicate that EDC-reacted DS had no effects on permeability. Figure 412B shows that as short as 10 minute incubation of 10 ng/mL VEGF, 30 µM QK, and 10 µM
DS-(peg2V)3 increased monolayer permeability compared to the non-treated media (EGM2-MV
lacking VEGF) and 10 µM EDC-reacted DS, although only the QK and DS-(peg2V)3 groups
showed statistically significant increases in our experiment. After 18 hours, the increases in
VEGF- and QK- induced permeability had disappeared, while DS-(peg2V)3 still maintained
significantly increased permeability (Figure 4-12B). By 24 hours, the permeability of DS(peg2V)3 treated wells recovered to control levels (Figure 4-12B). By extending treatments out
to 48 and 72 hours, both the VEGF and DS-(peg2V)3 treatments actually showed trending
decreases in monolayer permeability (Figure 4-12C). Both VEGF and DS-(peg2V)3 were
significantly different from untreated controls by 72 hours, and the effect of 10 µM DS-(peg2V)3
was statistically equivalent to 10 ng/mL VEGF (Figure 4-12C).
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Figure 4-12. HMVEC in vitro monolayer permeability assessed in Transwell chambers.

The endothelial cell monolayer provides a measurable decrease in permeability to a high
molecular weight 70kDa RITC-dextran (A). Both VEGF and QK stimulate transient
hyperpermeability that resolves within 18 hours of treatment whereas DS-peg2V3 has a slightly
prolonged hyperpermeable response that recovers by 24 hours (B). Peg2V conjugated to DS at a
substitution of 3 provides responses similar to VEGF, gradually tightening the monolayer after
24 hours of bolus treatments (C).
A preliminary study of the effects of free LXW7 and DS-(LXW7)4 in the transwell
system did not produce permeability effects comparable to VEGF treatment (data not shown).
Although other groups have reported that free LXW7 inhibits VEGF-mediated permeability
(176), we did not explore this property of free LXW7 in our transwell system because it would
be difficult to use these experiments to infer the vascular permeability effects of surface-bound
LXW7.
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4.5

Conclusions
In summary, we report two variants of pro-angiogenic decorin mimics conjugated with

VEGF-mimicking QK peptide and integrin-binding LXW7 peptide that activate VEGF pathways
through direct and indirect mechanisms, respectively. While LXW7-conjugated variants appear
to stimulate proliferation without VEGF, the peg2V-conjugated variant potentiated VEGF
proliferative responses. In solution, the longer linker of peg2V peptide was necessary to exert
effective proliferative response from the VEGF-mimicking sequence. Both (peg2V)3-DS-SILY4
and 4LXW7-DS-SILY4 variants stimulate endothelial migration. Furthermore, the proangiogenic decorin mimics increased EC tubule formation although networks were thinner,
shorter, and less branched. In vivo, CAM neovascularization into a collagen scaffold embedded
with pro-angiogenic decorin mimics demonstrated increased angiogenesis for treated gels,
although control gels on 4LXW7-DS-SILY4 treated chicks also exhibited increased vascularity.
Since pilot studies showed increased Evan’s blue and RITC-dextran accumulation at CAM
collagen gel implant sites, EC monolayer permeability was also assessed in vitro. We found that
peg2V conjugated to DS caused prolonged hyperpermeability that was not present with free QK.
However, over longer periods of treatment, the DS(peg2V)3 was able to reduce
hyperpermeability on a similar time scale as VEGF.
In addition to discussing the angiogenic activity of the two variants, these results support the
importance of peptide context in affecting bioactivity. We demonstrate that peg2V immobilized
to collagen surfaces by DS-SILY4 at low surface densities can stimulate migration and potentiate
proliferation. Our results also show that LXW7 presented in specific patterns and surface
densities could exhibit an amplified bioactive response, and that free LXW7 produces an antiangiogenic response. The data therefore highlights that soluble peptides can have a drastically
different response compared to surface-bound peptides and that densities promoting receptor
clustering may be beneficial in exploiting potentiated receptor activation.
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5. CONCLUSIONS

5.1

Conclusions and Future Directions
The complex pathophysiological environment of chronic ischemic diabetic foot ulcers

presents a significant challenge for angiogenic growth factor therapies. Through the chapters of
this dissertation, 3 therapies were proposed that could be used in combination and address
multiple aspects of impaired healing. The focus of chapter 2 was the development of a
nanoparticle system to protect and deliver VEGF over a sustained period of time to the wound
bed. Incremental improvements were made in a system designed to deliver anti-inflammatory
peptides in osteoarthritic models and the final improved system was adapted for VEGF loading
and release. However, although the developed system was able to achieve high loading
efficiency of VEGF, a very small fraction of the loaded VEGF was released and most of the
release occurred within the first 12 hours. As most of the VEGF was still trapped in the particle,
the particles’ release capacity could be improved by incorporating degradability.
The combined focus of chapters 3 and 4 was the development and characterization of proangiogenic decorin mimics that simultaneously protect healing tissue, stimulate
revascularization, and potentially recruit endothelial progenitor cells (in the case of LXW7-DSSILY4). Studies investigating endothelial recruitment by LXW7-DS-SILY4 are also underway.
As the (peg2V)3-DS-SILY4 and 5.5LXW7-DS-SILY4 variants demonstrated VEGF potentiation,
they would be appropriate therapies to combine with the VEGF-releasing nanoparticles. These
variants could also be administered alone as they would potentiate endogenous VEGF, and the
(peg2V)3-DS-SILY4 variant demonstrated revascularization efficacy in vivo. The lower
substitution LXW7-DS-SILY4 variants administered alone were shown to stimulate endothelial
proliferation and migration in vitro and revascularization in vivo, although further investigation
of the cause of increased vascularization in controls on LXW7-DS-SILY4 treated animals is
necessary as increased angiogenesis distant from the site of application is undesirable.
Moreover, our CAM study serves only as a proof-of-concept for stimulation of angiogenesis.
The next step in determining efficacy is to perform in vivo small animal studies specifically
investigating diabetic ischemic wound healing.
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Although we have shown angiogenic efficacy through proliferation, migration, and
vascularization of collagen gels, many more studies will help better characterize the bioactivity
of our molecules. First, with our limited understanding from 2D tubulogenesis assays, more in
depth examination of in vitro tubulogenesis using 3D models in collagen gels would better
characterize the angiogenic bioactivity. Further exploration of new vessel permeability is also
warranted. The studies determined that all collagen gels induced leaky vessels in the CAM
model, but pro-angiogenic decorin mimic-induced mimics might be leakier. In vitro assessment
of permeability demonstrated that conjugated Peg2V prolongs VEGF-induced permeability, but
has comparable effects to VEGF by tightening the endothelial barrier after several bolus
treatments over 72 hours. The effects are likely the result of differing receptor activation kinetics
and thus future dynamic studies of receptor activation and downstream second messengers would
help elucidate the angiogenic mechanisms.
Overall, the nanoparticle delivery of VEGF and two pro-angiogenic decorin mimic variants
show promise in tackling multiple aspects of disease in the diabetic wound. Given the two
different mechanisms of action and different pro-angiogenic responses that we observed, it
would also be interesting to conjugate both peptides simultaneously to exploit integrin-VEGF
receptor crosstalk. If these pro-angiogenic therapies can be proven clinically to provide
controlled, targeted angiogenesis, the engineered molecules could have even wider applications
to many types of ischemic wounds, including injured myocardium or ischemic bowel.
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